{"id": "batch_req_67fc1ff6fb788190a8e82ea5beac7692", "custom_id": "Furosemide-complexify", "response": {"status_code": 200, "request_id": "019c78e5690fd944caeec61668ab0ae4", "body": {"id": "chatcmpl-BLyJzhO4ZU531iiUfoCLLoWIyETw5", "object": "chat.completion", "created": 1744576463, "model": "gpt-4o-2024-08-06", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Furosemide, a potent loop diuretic, exerts its pharmacological action by inhibiting the Na-K-2Cl symporter in the thick ascending limb of the loop of Henle, thus profoundly augmenting natriuresis and diuresis, which alleviates conditions of edema secondary to cardiac, hepatic, or renal insufficiencies. Additionally utilized in the management of hypertension, furosemide yields rapid onset of action with intravenous administration effectuating within five minutes, whereas oral ingestion manifests systemic absorption and efficacy within an hour. Adverse effects encompass orthostatic hypotension, tinnitus, and photosensitivity, with severe risks including electrolyte imbalances such as hypokalemia, along with potential nephrotoxicity and ototoxicity. Clinicians are advised to diligently monitor serum electrolytes (notably potassium), bicarbonate, renal indices (creatinine, BUN), and hepatic function parameters. Despite its inclusion on the World Health Organization's List of Essential Medicines, furosemide's utility is tempered by its status on the World Anti-Doping Agency's list of prohibited substances, attributed to its potential misuse for concealing illicit performance-enhancing drug usage, alongside its veterinary application for managing exercise-induced pulmonary hemorrhage in equines.", "refusal": null, "annotations": []}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 526, "completion_tokens": 253, "total_tokens": 779, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 0, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": "fp_92f14e8683"}}, "error": null}
{"id": "batch_req_67fc1ff70ea88190828e4ebcb15c94f5", "custom_id": "Gabapentin-complexify", "response": {"status_code": 200, "request_id": "d099ab90ca93c71c2da9adb5fe946d99", "body": {"id": "chatcmpl-BLyJzPA6dbscD0f7eILMwrCFx1FWt", "object": "chat.completion", "created": 1744576463, "model": "gpt-4o-2024-08-06", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Gabapentin, a prototypical member of the gabapentinoid class, is extensively utilized in the management of neuropathic pain syndromes, including diabetic neuropathy and postherpetic neuralgia, as well as partial epileptic seizures. Its mechanism of action predominantly involves high-affinity binding to the \u03b12\u03b4-1 subunit of voltage-gated calcium channels, encoded by the CACNA2D1 gene, thereby attenuating the synaptic release of glutamate and consequent hyperexcitability within central neuronal circuits. Although effective in approximately 30-40% of patients with neuropathic pain, the pharmacodynamic profile necessitates cautious administration, particularly in patients with renal impairment, due to its propensity to induce sedation, dizziness, potential for respiratory depression, and a heightened suicidality risk as classified by the FDA. Gabapentin's pharmacokinetic traits and adverse event profile require vigilant therapeutic monitoring to mitigate risks and optimize clinical outcomes. It continues to be a staple in therapeutic regimens, as evidenced by its status as one of the most prescribed medications in the United States, albeit historical controversies concerning its marketing strategies by the originating pharmaceutical entities.", "refusal": null, "annotations": []}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 539, "completion_tokens": 235, "total_tokens": 774, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 0, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": "fp_92f14e8683"}}, "error": null}
{"id": "batch_req_67fc1ff722948190999153f93bfc66cd", "custom_id": "Duloxetine-complexify", "response": {"status_code": 200, "request_id": "e6e63d629941dea44b95704a0137a4d9", "body": {"id": "chatcmpl-BLyJz2fqKmPk81OKhHlZy7qnIkJrv", "object": "chat.completion", "created": 1744576463, "model": "gpt-4o-2024-08-06", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Duloxetine, a pharmacological agent classified as a serotonin\u2013norepinephrine reuptake inhibitor (SNRI), exhibits efficacy in ameliorating symptoms associated with major depressive disorder, generalized anxiety disorder, obsessive\u2013compulsive disorder, fibromyalgia, neuropathic pain, and central sensitization by modulating the synaptic reuptake mechanisms of neurotransmitters. While the exact molecular pathways underlying its therapeutic anxiolytic and antidepressant effects remain elusive, duloxetine's engagement with serotonergic and noradrenergic systems is hypothesized to play a critical role. Adverse events frequently encountered include xerostomia, nausea, asthenia, vertigo, psychomotor agitation, sexual dysfunction, and hyperhidrosis, while the drug also poses risks of severe outcomes such as heightened suicidality, serotonin toxicity, manic episodes, hepatotoxicity, and teratogenic effects if administered during late gestation. Additionally, abrupt cessation of duloxetine may precipitate antidepressant discontinuation syndrome. Marketed as both branded and generic formulations, duloxetine figures prominently in psychopharmacology, ranking among the most prescribed medications with significant prevalence, underscoring its entrenched role in contemporary clinical practice.", "refusal": null, "annotations": []}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 353, "completion_tokens": 243, "total_tokens": 596, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 0, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": "fp_92f14e8683"}}, "error": null}
{"id": "batch_req_67fc1ff739888190b3ac6ee3a4858496", "custom_id": "Benazepril-complexify", "response": {"status_code": 200, "request_id": "2e0ff6474bfa4022b08a9ef340479e2a", "body": {"id": "chatcmpl-BLyJzbS7j0alg0TiSJiI0eaQk9LNO", "object": "chat.completion", "created": 1744576463, "model": "gpt-4o-2024-08-06", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Benazepril, an ACE inhibitor marketed as Lotensin, is administered orally for the management of hypertension, heart failure, and diabetic nephropathy by attenuating the renin-angiotensin-aldosterone system activity. Formulations include benazepril/hydrochlorothiazide and benazepril/amlodipine combinations, targeting synergistic pathways for antihypertensive efficacy. The pharmacodynamic profile includes adverse reactions such as asthenia, orthostatic dizziness, and cough, while severe adverse events consist of potential nephrotoxicity, hypotension, hyperkalemia, and angioedema. Teratogenic risks disallow its use during gestation, contrasting with permissible lactational use. Its pharmacokinetic properties have secured its status as a widely prescribed, generic therapeutic, illustrated by over three million prescriptions in the U.S. in 2022.", "refusal": null, "annotations": []}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 352, "completion_tokens": 182, "total_tokens": 534, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 0, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": "fp_92f14e8683"}}, "error": null}
{"id": "batch_req_67fc1ff74e6c8190b0583e52b4fe3f8f", "custom_id": "Haloperidol-complexify", "response": {"status_code": 200, "request_id": "16e9a96d722108af328ee949bc006662", "body": {"id": "chatcmpl-BLyJz8iQutMzS6Am5hNfKe3JZYy6G", "object": "chat.completion", "created": 1744576463, "model": "gpt-4o-2024-08-06", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Haloperidol, a butyrophenone derivative, exerts its therapeutic efficacy as a typical antipsychotic primarily through potent antagonism of central dopaminergic D2 receptors, ameliorating positive psychotic symptoms in conditions such as schizophrenia, Tourette syndrome, acute mania in bipolar disorder, delirium, and alcohol withdrawal-related hallucinations. Exhibiting rapid onset post-oral or parenteral administration, haloperidol can be deployed via bi-weekly intramuscular depot injections for long-term management of schizophrenia spectrum disorders in non-compliant patients. While efficacious, haloperidol is implicated in extrapyramidal side effects, notably irreversible tardive dyskinesia and akathisia, along with the rare but severe neuroleptic malignant syndrome and dose-dependent QT interval prolongation, the latter significantly observed with intravenous routes. Its contraindication in patients with Parkinson's disease and increased mortality risk in dementia-related psychosis underscore the necessity for judicious application. Adverse fetal outcomes restrict its use during pregnancy. Despite these safety concerns, haloperidol maintains its status as an essential medication per the World Health Organization's compendium, continually ranking among the most prescribed antipsychotics in clinical practice.", "refusal": null, "annotations": []}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 448, "completion_tokens": 244, "total_tokens": 692, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 0, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": "fp_92f14e8683"}}, "error": null}
{"id": "batch_req_67fc1ff761ac81909185b59e11c25d79", "custom_id": "Telmisartan-complexify", "response": {"status_code": 200, "request_id": "76c4e662a982352eb86ebec5622023f9", "body": {"id": "chatcmpl-BLyJzRqlmHqp1SJwnegDC3wLHKco5", "object": "chat.completion", "created": 1744576463, "model": "gpt-4o-2024-08-06", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Telmisartan, an angiotensin II receptor antagonist, is efficacious in the modulation of hypertension and heart failure via oral administration. It operates by antagonizing the angiotensin II AT1 receptor, thereby mitigating vasoconstrictive, aldosterone-secreting, and proliferative actions of angiotensin II. Clinically, it significantly reduces systemic vascular resistance and subsequently lowers blood pressure. While the therapeutic index is favorable, adverse effects such as upper respiratory tract infections, gastrointestinal disturbances, and lumbar discomfort are noted, with more severe complications including renal impairment, hypotension, and angioedema. Telmisartan is contraindicated during pregnancy due to potential teratogenicity and is not advised during lactation. It is frequently formulated in combination with diuretics or calcium channel blockers, like hydrochlorothiazide, cilnidipine, and amlodipine, to enhance antihypertensive efficacy.", "refusal": null, "annotations": []}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 362, "completion_tokens": 185, "total_tokens": 547, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 0, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": "fp_92f14e8683"}}, "error": null}
{"id": "batch_req_67fc1ff775a081908cfc088c2c64fc0f", "custom_id": "Diazepam-complexify", "response": {"status_code": 200, "request_id": "cdfbb851c9f37f081b04acd3a175b52e", "body": {"id": "chatcmpl-BLyJzrVkX19z90hj4IxoacaGSqN31", "object": "chat.completion", "created": 1744576463, "model": "gpt-4o-2024-08-06", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Diazepam, a prototypical member of the benzodiazepine pharmacological class, functions primarily as an anxiolytic by potentiation of GABAergic neurotransmission, enhancing the binding affinity of gamma-aminobutyric acid (GABA) at the GABA_A receptor complex. It is employed in the management of a diverse array of conditions, including, but not limited to, generalized anxiety disorder, status epilepticus, alcohol withdrawal delirium, spasticity, insomnia, and restless legs syndrome, with additional utility in procedural amnesia induction. Diazepam exhibits versatile administration routes\u2014oral, rectal, intramuscular, intravenous, and intranasal, with IV administration eliciting rapid onset of action within 1-5 minutes and demonstrating a relatively short duration of clinical efficacy. Oral administration results in peak plasma concentrations within 15 to 60 minutes. While generally well-tolerated, its adverse effect profile includes CNS depression manifesting as sedation and impaired motor coordination, with rare, yet severe risks like respiratory depression, paradoxical excitation, and seizure exacerbation with chronic use. Chronic administration raises the risk of tolerance, physical dependence, and a withdrawal syndrome upon abrupt cessation; cognitive impairments post-discontinuation are well-documented. It is contraindicated in pregnancy and lactation due to teratogenic and neonatal withdrawal potential. Diazepam continues to be a mainstay therapeutic agent on the World Health Organization\u2019s List of Essential Medicines, despite its risk for abuse and dependency, underscoring the necessity for judicious prescribing practice.", "refusal": null, "annotations": []}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 551, "completion_tokens": 313, "total_tokens": 864, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 0, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": "fp_92f14e8683"}}, "error": null}
{"id": "batch_req_67fc1ff789948190bf40abdea575b8c8", "custom_id": "Celecoxib-complexify", "response": {"status_code": 200, "request_id": "5fbc9b4f0da2adb057f39e425d650873", "body": {"id": "chatcmpl-BLyJzTJ3imVk9ovAZ9plfht59goWF", "object": "chat.completion", "created": 1744576463, "model": "gpt-4o-2024-08-06", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Celecoxib, a selective cyclooxygenase-2 (COX-2) inhibitor, functions as a nonsteroidal anti-inflammatory drug (NSAID) utilized primarily for its analgesic and anti-inflammatory efficacy in osteoarthritis, rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, dysmenorrhea, acute pain management, and juvenile rheumatoid arthritis. Additionally, celecoxib has prophylactic applications in reducing colorectal adenomatous formations in familial adenomatous polyposis due to its COX-2 inhibition, which mitigates pro-inflammatory prostaglandin synthesis while sparing COX-1, ostensibly minimizing gastrointestinal mucosal damage relative to non-selective NSAIDs. The pharmacokinetics permit oral administration, with pharmacodynamic effects commencing typically within one hour post-ingestion. Notable adverse reactions span gastrointestinal disturbances such as abdominal pain, nausea, and diarrhea, with severe risk profiles including cardiovascular thrombotic events, gastrointestinal perforation, renal impairment, and hypersensitivity reactions like anaphylaxis, contraindicating its use in populations with significant cardiovascular risk profiles. The risk profile parallels that of other NSAIDs like ibuprofen and naproxen, and caution is advised during late-stage gestation and lactation. Celecoxib's generic availability and widespread prescription underscore its clinical significance, albeit with requisite consideration of its potential side-effect burden.", "refusal": null, "annotations": []}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 392, "completion_tokens": 278, "total_tokens": 670, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 0, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": "fp_92f14e8683"}}, "error": null}
{"id": "batch_req_67fc1ff79ef0819082a5445881a9f3e9", "custom_id": "Sibutramine-complexify", "response": {"status_code": 200, "request_id": "a07fa5cd47f611257b0e652594d16743", "body": {"id": "chatcmpl-BLyK0TJ4yxueZ4B9mbcxyECxX2umb", "object": "chat.completion", "created": 1744576464, "model": "gpt-4o-2024-08-06", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Sibutramine, a pharmacological intervention formerly indicated for obesity management, operates through its mechanism as a serotonin\u2013norepinephrine reuptake inhibitor (SNRI), akin to certain antidepressant modalities, modulating monoamine neurotransmitter pathways to exert anorectic effects. Despite its initial widespread utilization, it was contraindicated due to a correlation with augmented cardiovascular morbidity and cerebrovascular incidents, prompting market withdrawal across multiple jurisdictions including Australia, the European Union, and the United States by 2010. Developed by Boots Pharmaceuticals and subsequently commercialized by Abbott Laboratories under trade names such as Meridia and Reductil, sibutramine was a Schedule IV controlled entity in the United States before its discontinuation. However, the compound persists in unregulated domains, as evidenced by FDA findings of its presence in numerous purported \"natural\" or \"herbal\" supplements as recently as 2018, underscoring challenges in illicit pharmacovigilance.", "refusal": null, "annotations": []}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 412, "completion_tokens": 192, "total_tokens": 604, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 0, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": "fp_92f14e8683"}}, "error": null}
{"id": "batch_req_67fc1ff7b2c881909c25e1739c72e656", "custom_id": "Fenofibrate-complexify", "response": {"status_code": 200, "request_id": "f203783adda9df8467df3cde64a184ce", "body": {"id": "chatcmpl-BLyK04L41uBeAPtRg14wXBFqHx8Ru", "object": "chat.completion", "created": 1744576464, "model": "gpt-4o-2024-08-06", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Fenofibrate, a lipid-modifying agent of the fibrate class, functions primarily through agonism of the peroxisome proliferator-activated receptor alpha (PPAR\u03b1), effectuating enhanced oxidation of fatty acids, increased lipoprotein lipase synthesis, and reduced hepatic production of apolipoprotein C-III, thereby leading to a reduction in triglyceride levels and modification of low-density lipoprotein (LDL) particle size. Its therapeutic efficacy, particularly in dyslipidemic profiles characterized by hypertriglyceridemia and low HDL cholesterol, albeit less statistically robust compared to HMG-CoA reductase inhibitors (statins), offers cardioprotective benefits within select demographic cohorts predisposed to atherogenic dyslipidemia. Gastrointestinal disturbances, hepatotoxicity, myopathy, and hypersensitivity reactions such as toxic epidermal necrolysis can manifest as dose-related adverse effects, while contraindications include pregnancy and lactation due to teratogenic potential. Despite its availability as a cost-effective generic, fenofibrate's clinical application necessitates concurrent dietary management to maximize therapeutic outcomes and mitigate risks of severe adverse sequelae like rhabdomyolysis, pancreatitis, and cholelithiasis.", "refusal": null, "annotations": []}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 381, "completion_tokens": 251, "total_tokens": 632, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 0, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": "fp_92f14e8683"}}, "error": null}
{"id": "batch_req_67fc1ff7c94c8190afc050649e67b711", "custom_id": "Rosiglitazone-complexify", "response": {"status_code": 200, "request_id": "f8d9dace07a652655589726b1cba11a2", "body": {"id": "chatcmpl-BLyK1BkL2rSEAQHw29ESlYOA45Vzc", "object": "chat.completion", "created": 1744576465, "model": "gpt-4o-2024-08-06", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Rosiglitazone is a thiazolidinedione-class pharmacologic agent that acts as a peroxisome proliferator-activated receptor gamma (PPAR\u03b3) agonist, facilitating enhanced insulin sensitivity in adipocytes. Despite demonstrating efficacy in glycemic modulation for Type 2 diabetes mellitus via its action on PPAR\u03b3, concerns regarding cardiovascular risk emerged, precipitating a precipitous decline in utilization post-2007 after meta-analytic data implicated it in myocardial infarction risk augmentation. This prompted the European Medicines Agency to recommend its market withdrawal due to an unfavorable risk-benefit profile, whereas the FDA, after imposing stringent prescription controls, eventually rescinded such requirements following re-evaluation of cardiovascular outcomes in subsequent trials. Rosiglitazone's commercial trajectory reflects contentious safety profiles, culminating in extensive litigation against GlaxoSmithKline, despite its continued availability in the U.S. under regulated conditions, contrasting with withdrawal from multiple international markets due to regulatory edicts.", "refusal": null, "annotations": []}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 597, "completion_tokens": 196, "total_tokens": 793, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 0, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": "fp_92f14e8683"}}, "error": null}
{"id": "batch_req_67fc1ff7db4c8190bf8ab8a124e25345", "custom_id": "Azelastine-complexify", "response": {"status_code": 200, "request_id": "af1be5acc8d3a5243b2a5a2a0a13c25d", "body": {"id": "chatcmpl-BLyK5rQgnpjOHcRafHfhNYnXM45wY", "object": "chat.completion", "created": 1744576469, "model": "gpt-4o-2024-08-06", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Azelastine functions as a second-generation H1 receptor antagonist with multifaceted applications, notably as a nasal spray for allergic rhinitis and ocular drops for allergic conjunctivitis, while also exhibiting utility in the management of asthma and dermal hypersensitivity reactions via oral administration. Its pharmacodynamics involve rapid onset, with ocular effects manifesting within minutes and intranasal effects appearing within an hour, sustained for up to 12 hours. This antihistaminic agent exerts its therapeutic efficacy by impeding the release of inflammatory mediators, prominently histamine, thus mitigating allergic symptomatology. The adverse effect profile includes cephalalgia, somnolence, dysgeusia, and pharyngitis, with its safety profile during gestation and lactation remaining ambiguous. Azelastine's widespread usage is reflected in its substantial prescription frequency, denoting its significance in the therapeutic landscape.", "refusal": null, "annotations": []}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 346, "completion_tokens": 178, "total_tokens": 524, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 0, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": "fp_92f14e8683"}}, "error": null}
{"id": "batch_req_67fc1ff7ee808190997acbf05df9d15b", "custom_id": "Ranitidine-complexify", "response": {"status_code": 200, "request_id": "67620a365b35999e67c8652b546e5e58", "body": {"id": "chatcmpl-BLyK7YEAWU1O2t74ArcDFtJccgFsv", "object": "chat.completion", "created": 1744576471, "model": "gpt-4o-2024-08-06", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Ranitidine, an H2 histamine receptor antagonist, functions by inhibiting histamine stimulation of gastric parietal cells, thereby attenuating gastric acid secretion; this pharmacological blockade has historically positioned it as a therapeutic agent for acid-related disorders such as peptic ulcer disease, gastroesophageal reflux disease, and Zollinger-Ellison syndrome. Available in oral, intramuscular, and intravenous formulations, ranitidine's clinical utility was overshadowed by the detection of N-nitrosodimethylamine (NDMA), a potential carcinogen, within its preparations, leading to global concerns and market withdrawal. Subsequent epidemiological investigations, including a comprehensive Taiwanese cohort analysis, underscore a statistically significant dose-response correlation between ranitidine exposure and hepatocarcinogenesis, alongside elevated oncogenic risks across gastric, pancreatic, osseous, and pulmonary systems. While its adverse effect profile ranges from common occurrences such as cephalalgia to severe pathologies including carcinogenicity, hepatic dysfunction, bradycardia, and infection propensity, the risk of concealing neoplasms like gastric carcinoma has prompted heightened scrutiny. The agent's association with Clostridioides difficile colitis further complicates its safety landscape, ultimately resulting in its removal from essential medicine lists and cessation of its availability in principal healthcare markets.", "refusal": null, "annotations": []}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 485, "completion_tokens": 264, "total_tokens": 749, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 0, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": "fp_a6dfaf2bcf"}}, "error": null}
{"id": "batch_req_67fc1ff801708190af9aff55478c37c8", "custom_id": "Methylphenidate-complexify", "response": {"status_code": 200, "request_id": "0ef5efcd6c606d5bd49f281d3d0e17d8", "body": {"id": "chatcmpl-BLyK934eFb2OAaRalWQ1GHbh3ywa3", "object": "chat.completion", "created": 1744576473, "model": "gpt-4o-2024-08-06", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Methylphenidate, a CNS stimulant within the phenethylamine and piperidine classes, exerts therapeutic effects in ADHD and narcolepsy predominantly through the inhibition of presynaptic dopamine and norepinephrine transporters, thereby augmenting synaptic monoamine concentrations. Its pharmacodynamics establish a clinical efficacy for enhancing executive functions such as attentional control, inhibitory processes, working memory, and emotional regulation, albeit with a slightly reduced efficacy compared to amphetamines. Pharmacokinetically, methylphenidate is amenable to both oral and transdermal administration with formulation-dependent pharmacokinetics dictating therapeutic windows. Adverse effects span neuropsychiatric and autonomic domains, including, but not limited to, sympathomimetic manifestations such as tachycardia, euphoria, anorexia, and insomnia, while withdrawal is typified by dysphoric and neurovegetative symptoms. Methylphenidate's status as a high-frequency prescription medication is underscored by its extensive dispensation, ranking as the 32nd most prescribed medication in the U.S. as of 2022, available in both branded and generic forms.", "refusal": null, "annotations": []}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 445, "completion_tokens": 234, "total_tokens": 679, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 0, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": "fp_92f14e8683"}}, "error": null}
{"id": "batch_req_67fc1ff8169081908ccc70e2036a1424", "custom_id": "Propofol-complexify", "response": {"status_code": 200, "request_id": "a385ea41bc6597ae6d7af1956ff514f4", "body": {"id": "chatcmpl-BLyKFgVctTqOVLTeexB1k2SGwqzqG", "object": "chat.completion", "created": 1744576479, "model": "gpt-4o-2024-08-06", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Propofol, a 2,6-diisopropylphenol compound, serves as a cornerstone intravenous agent for induction and maintenance of general anesthesia, leveraging its rapid onset and rapid clearance pharmacokinetics for broad clinical applicability, including peri-procedural sedation and the management of refractory status epilepticus. Administered as a sterile, lipid-based emulsion incorporating soy-based triglycerides and egg-derived lecithin, this formulation's distinct milky appearance underscores its non-aqueous solubility requisites. Propofol elicits unconsciousness expeditiously upon bolus administration and facilitates smooth maintenance via infusion strategies, attributed to its GABA_A receptor agonism which potentiates inhibitory neurotransmission and culminates in reduced synaptic excitability. Its clinical advantage is underscored by an attenuated profile of postoperative sedation-related adverse effects, namely residual drowsiness, nausea, and vomiting, rivalling alternative anesthetic agents. As a critical agent on the WHO List of Essential Medicines, its utility spans diagnostic, surgical, and emergency care contexts, although administration mandates diligent monitoring due to potential for hemodynamic and respiratory modulation.", "refusal": null, "annotations": []}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 427, "completion_tokens": 231, "total_tokens": 658, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 0, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": "fp_a6dfaf2bcf"}}, "error": null}
{"id": "batch_req_67fc1ff827fc8190ab38438f04330d40", "custom_id": "Darunavir-complexify", "response": {"status_code": 200, "request_id": "02e9c502ca730f4f79a35bffd4e49ae2", "body": {"id": "chatcmpl-BLyKI5HbVSV63spgmO7edumOl7D4h", "object": "chat.completion", "created": 1744576482, "model": "gpt-4o-2024-08-06", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Darunavir (DRV) is an antiretroviral protease inhibitor utilized primarily for the therapeutic regimen of HIV/AIDS, necessitating concomitant administration with pharmacokinetic enhancers such as ritonavir or cobicistat to potentiate systemic bioavailability. DRV performs its mechanism of action through the inhibition of the HIV-1 protease enzyme, thus impairing viral polyprotein processing and subsequent viral maturation. Clinical administration can be post-exposure prophylaxis, particularly following potential occupational or non-occupational exposure. Adverse effects manifest variably from gastrointestinal disturbances to severe dermatological reactions including toxic epidermal necrolysis, with hepatotoxicity noted as a critical consideration. While teratogenic data remains limited, current clinical evidence suggests relative neonatal safety. Commercial formulations include combination therapies like darunavir/cobicistat (Prezcobix, Rezolsta) and darunavir/cobicistat/emtricitabine/tenofovir alafenamide (Symtuza), presenting enhanced compliance through reduced dosing complexity.", "refusal": null, "annotations": []}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 403, "completion_tokens": 206, "total_tokens": 609, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 0, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": "fp_92f14e8683"}}, "error": null}
{"id": "batch_req_67fc1ff83cb48190800fdd0995253e85", "custom_id": "desvenlafaxine-complexify", "response": {"status_code": 200, "request_id": "6e38f5c3f893d0a5a4aca03acdad50b8", "body": {"id": "chatcmpl-BLyKK0WK3Tw7dppItXK83Man6f8Dp", "object": "chat.completion", "created": 1744576484, "model": "gpt-4o-2024-08-06", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Desvenlafaxine, a potent SNRI antidepressant clinically designated for major depressive disorder, exerts its pharmacological effects via inhibition of presynaptic serotonin and norepinephrine transporters, thereby augmenting synaptic concentrations of these neurotransmitters. Administered orally, its therapeutic efficacy necessitates periodic reevaluation to ascertain continued benefit relative to its progenitor compound, venlafaxine, with mixed comparative results reported. Adverse event profiles include central nervous system perturbations such as dizziness and somnolence, autonomic dysregulation manifesting as hyperhidrosis and hypertension, gastrointestinal disturbances like constipation, and sexual dysfunction, alongside the potential for eliciting severe psychiatric and systemic crises such as serotonin syndrome, manic episodes, and hemorrhagic events. The abrupt cessation of desvenlafaxine is contraindicated due to a significant risk of withdrawal syndrome. Teratogenic and lactational safety remains inadequately characterized. Despite its prevalent prescription status in the United States, regulatory approval within the European context was not attained, underscoring variances in regional pharmaco-therapeutic standards.", "refusal": null, "annotations": []}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 375, "completion_tokens": 221, "total_tokens": 596, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 0, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": "fp_92f14e8683"}}, "error": null}
{"id": "batch_req_67fc1ff85a088190b8b9c99347a55795", "custom_id": "Indapamide-complexify", "response": {"status_code": 200, "request_id": "4c26d01b9baacacc63dc4d4b5e645520", "body": {"id": "chatcmpl-BLyKMU1quWSIaWttHjc4i0WTNSnY4", "object": "chat.completion", "created": 1744576486, "model": "gpt-4o-2024-08-06", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Indapamide, a thiazide-like sulfonamide diuretic, is employed primarily in mitigating hypertension and addressing decompensated heart failure, functioning by inhibiting sodium reabsorption at the distal convoluted tubule, which consequently enhances renal excretion of sodium and water, thereby reducing plasma volume and vascular resistance. Its efficacy parallels that of traditional thiazide diuretics and, in combination with perindopril, exerts an enhanced antihypertensive synergy. Indapamide demonstrates a favorable cardiovascular profile, attenuating risks associated with major events and heart failure in hypertensive cohorts, akin to chlorthalidone, and shows superior outcomes compared to hydrochlorothiazide. Moreover, both thiazide and thiazide-like diuretics effectively minimize stroke incidence, maintaining safety profiles comparable to other antihypertensive classes such as angiotensin II receptor antagonists and dihydropyridine calcium antagonists, while exhibiting a diminished spectrum of adverse effects relative to ACE inhibitors and non-dihydropyridine calcium blockers, thus occupying a critical niche in essential therapeutic regimens.", "refusal": null, "annotations": []}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 347, "completion_tokens": 224, "total_tokens": 571, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 0, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": "fp_92f14e8683"}}, "error": null}
{"id": "batch_req_67fc1ff86ce8819083c0f1c3ebfd5f82", "custom_id": "Ofloxacin-complexify", "response": {"status_code": 200, "request_id": "9f5e91e39e2f1816e52de8b1f2402308", "body": {"id": "chatcmpl-BLyKPojnKWdK8F7hnGqhdUDlYBXmQ", "object": "chat.completion", "created": 1744576489, "model": "gpt-4o-2024-08-06", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Ofloxacin, a member of the fluoroquinolone class, functions as a DNA synthesis inhibitor by targeting bacterial DNA gyrase and topoisomerase IV, making it efficacious against an array of bacterial pathogens. Clinically, ofloxacin is administered orally or intravenously for conditions such as pneumonia, cellulitis, urinary tract infections, prostatitis, and plague, with combination protocols extending its utility to multidrug-resistant tuberculosis. Furthermore, ophthalmic formulations address superficial ocular infections, while otic solutions are effective for otitis media complicated by tympanic membrane perforation. However, its pharmacotherapeutic profile is burdened by adverse effects like gastrointestinal disturbances, CNS involvement manifesting as headaches or psychosis, and peripheral neuropathy leading to limb paresthesia or tendon rupture, making it contraindicated during pregnancy. Despite these side effects, ofloxacin maintains a pivotal role in antimicrobial therapy, underscored by its inclusion in the World Health Organization's List of Essential Medicines amid widespread prescription as a generic formulation.", "refusal": null, "annotations": []}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 379, "completion_tokens": 201, "total_tokens": 580, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 0, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": "fp_92f14e8683"}}, "error": null}
{"id": "batch_req_67fc1ff880d481908520fb9fa937f96b", "custom_id": "Dapsone-complexify", "response": {"status_code": 200, "request_id": "c50e528df591ec7dcf8159520e52cf68", "body": {"id": "chatcmpl-BLyKRQg04QoLkbEOqZbYbXbgkqO0E", "object": "chat.completion", "created": 1744576491, "model": "gpt-4o-2024-08-06", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Dapsone, chemically delineated as 4,4'-sulfonyldianiline or diaminodiphenyl sulfone, operates as a bacteriostatic antimicrobial agent within the sulfone class, frequently co-administered with rifampicin and clofazimine in leprosy management. It serves as an adjunctive therapeutic in pneumocystis pneumonia prophylaxis and toxoplasmosis prevention within immunocompromised cohorts, as well as for dermatological conditions such as acne and dermatitis herpetiformis, available in both oral and topical formulations. Pharmacodynamically, dapsone's modes of action encompass inhibition of bacterial dihydropteroate synthetase, although it is associated with grave hematological adverse effects, notably hemolytic anemia exacerbated by glucose-6-phosphate dehydrogenase deficiency and agranulocytosis, alongside potential hepatotoxicity manifested as hepatic inflammation. Methemoglobinemia and dermatological hypersensitivity reactions, encompassing a variety of rash presentations, constitute additional risk factors. The teratogenic profile remains equivocal; however, continuation during gestation is advised in leprosy cases. Economically accessible as a generic formulation, dapsone retains its inclusion on the WHO Essential Medicines List, underscoring its clinical utility and indispensable status in global health pharmacopeias.", "refusal": null, "annotations": []}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 430, "completion_tokens": 273, "total_tokens": 703, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 0, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": "fp_a6dfaf2bcf"}}, "error": null}
{"id": "batch_req_67fc1ff8932c8190b337b9d57f268488", "custom_id": "Temazepam-complexify", "response": {"status_code": 200, "request_id": "77957d9e09238d1f9fad7cab77eecb6c", "body": {"id": "chatcmpl-BLyKUBkHLS8Mi3t57yMSmZTUkG4HR", "object": "chat.completion", "created": 1744576494, "model": "gpt-4o-2024-08-06", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Temazepam is a benzodiazepine class hypnotic agent indicated primarily for the management of severe insomnia, characterized by its rapid oral absorption with clinically significant hypnotic and anxiolytic actions initiating within 30 minutes and persisting for approximately eight hours. The pharmacodynamic efficacy is mediated via positive allosteric modulation of the GABA-A receptor, enhancing GABAergic neurotransmission and inducing sedative-hypnotic outcomes. Despite its historical utilization, the prescription prevalence has diminished, supplanted by z-drugs and certain atypical antidepressants due to a more favorable side effect profile. Temazepam\u2019s pharmacokinetic and safety concerns include side effects such as ataxia, cognitive dysfunction, and in severe cases, can escalate to hallucinations, hypotension, and potential respiratory depression, particularly when co-administered with CNS depressants like alcohol or opioids. The withdrawal syndrome poses a significant risk upon rapid cessation following prolonged use. Teratogenic concerns contraindicate use during pregnancy and lactation. Despite its historical ubiquity as evidenced by over two million prescriptions in 2021, the clinical positioning of temazepam now leans towards refractory insomnia cases where alternative pharmacotherapy has been deemed inadequate.", "refusal": null, "annotations": []}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 489, "completion_tokens": 244, "total_tokens": 733, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 0, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": "fp_92f14e8683"}}, "error": null}
{"id": "batch_req_67fc1ff8a43c8190b7724e9a29e2b818", "custom_id": "Pilocarpine-complexify", "response": {"status_code": 200, "request_id": "84f6b5daa0f929f287299975785f9895", "body": {"id": "chatcmpl-BLyKXCxqeFqBAlIojZGT1tDuCnoQY", "object": "chat.completion", "created": 1744576497, "model": "gpt-4o-2024-08-06", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Pilocarpine, a muscarinic agonist in the miotics pharmacological class, exerts its therapeutic effects primarily through cholinergic receptor activation, specifically targeting muscarinic acetylcholine receptors to facilitate aqueous humor outflow via the trabecular meshwork. While its ophthalmic formulation is indicated for acute intervention in angle-closure glaucoma, ocular hypertension, and primary open-angle glaucoma, its utility is limited in chronic management due to adverse effects such as ocular irritation, lacrimation increase, cephalalgia, and transient visual disturbances, with potential complications including retinal detachment and hypersensitivity reactions. Pilocarpine's pharmacodynamics involve onset within one hour with effects persisting up to 24 hours. Systemic administration is employed in xerostomia management secondary to Sj\u00f6gren syndrome or post-radiation sequelae. Nonetheless, its use contraindicated during pregnancy underscores its safety profile concerns. Initially derived from Pilocarpus spp., pilocarpine remains inextricably linked to its historical provenance yet maintains its clinical relevance as delineated in the WHO Essential Medicines list.", "refusal": null, "annotations": []}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 432, "completion_tokens": 222, "total_tokens": 654, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 0, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": "fp_92f14e8683"}}, "error": null}
{"id": "batch_req_67fc1ff8b7608190b4beb0ba7fa788d9", "custom_id": "Formoterol-complexify", "response": {"status_code": 200, "request_id": "4a27714297f7f165e3a4da80a6cd1771", "body": {"id": "chatcmpl-BLyKaxMHLQzFIqzBDXIofX1rB1Rgk", "object": "chat.completion", "created": 1744576500, "model": "gpt-4o-2024-08-06", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Formoterol, a potent long-acting \u03b22-adrenergic receptor agonist (LABA), functions as a bronchodilator specifically targeting pulmonary smooth muscle to induce bronchodilation, thereby offering therapeutic utility in the management of asthma and chronic obstructive pulmonary disease (COPD). Notably, formoterol distinguishes itself by a prolonged bronchodilatory efficacy of approximately 12 hours post-administration, surpassing the 4-6 hour window typical of short-acting \u03b22 agonists like salbutamol (albuterol). Its pharmacokinetic profile is characterized by a rapid onset of action within 2-3 minutes, setting it apart from other LABAs. According to the 2022 Global Initiative for Asthma guidelines, adult treatment regimens favor a formoterol and inhaled corticosteroid combination for both prophylactic and acute symptom management, whereas pediatric protocols prioritize short-acting \u03b22 adrenergic agonists, such as salbutamol for immediate relief. Formoterol is commercially available both as a standalone generic medication and in synergistic fixed-dose combinations, notably with budesonide and mometasone, to enhance its clinical efficacy in targeted therapeutic strategies.", "refusal": null, "annotations": []}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 371, "completion_tokens": 241, "total_tokens": 612, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 0, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": "fp_a6dfaf2bcf"}}, "error": null}
{"id": "batch_req_67fc1ff8cbf88190b1d792b4fae2c859", "custom_id": "Fluorouracil-complexify", "response": {"status_code": 200, "request_id": "77a69aba50fc9ed7d70dcd86e36c50c2", "body": {"id": "chatcmpl-BLyK14ovWdBe8k5n1fXkTQkuhTsqo", "object": "chat.completion", "created": 1744576465, "model": "gpt-4o-2024-08-06", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Fluorouracil (5-FU), commercially known as Adrucil, is a pyrimidine analog and antimetabolite cytotoxic agent, pivotal in the chemotherapeutic regimens for colorectal, oesophageal, gastric, pancreatic, mammary, and cervical carcinomas. Administered via intravenous infusion, its mechanistic action primarily entails inhibition of thymidylate synthase, impairing DNA synthesis by disrupting de novo pyrimidine biosynthesis, though the precise molecular pathways remain partially elucidated. Topically formulated, its indications extend to dermatological conditions such as actinic keratosis and basal cell carcinoma. Systemic administration commonly manifests toxicity profiles inclusive of mucositis, anorexia, myelosuppression, alopecia, and dermal inflammation; topical application predominantly results in localized irritation. Teratogenic potential contraindicates its utilization during gestation. Notwithstanding its adverse event spectrum, fluorouracil retains its status as an integral component of the WHO's Model List of Essential Medicines, underscoring its clinical utility in global oncology practices and dermatological applications.", "refusal": null, "annotations": []}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 412, "completion_tokens": 221, "total_tokens": 633, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 0, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": "fp_92f14e8683"}}, "error": null}
{"id": "batch_req_67fc1ff8de3c819081e9c9ff87d8ad5b", "custom_id": "Thalidomide-complexify", "response": {"status_code": 200, "request_id": "5888015ed50bee7a7ceddbed2a413e90", "body": {"id": "chatcmpl-BLyK1w5DrfIwpZFu0ISwWSpqAFp55", "object": "chat.completion", "created": 1744576465, "model": "gpt-4o-2024-08-06", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Thalidomide is an orally administered immunomodulatory drug widely utilized in the treatment of hematological malignancies such as multiple myeloma, graft-versus-host disease, and dermatological complications stemming from leprosy, while concurrently exhibiting therapeutic efficacy in addressing various HIV-associated pathological manifestations, including aphthous ulcers, wasting syndrome, diarrhea, and Kaposi's sarcoma. Its pharmacodynamic profile, however, is complicated by adverse side effects ranging from somnolence and dermatological reactions to severe toxicities like tumor lysis syndrome, thromboembolic events, and neurotoxic peripheral neuropathy. Esteemed for its teratogenic potential, thalidomide is notorious for inducing profound embryopathy characterized by dysmelia, phocomelia, and cardial, ocular, renal, and skeletal anomalies, with a teratogenic threshold reached at minimal exposure levels, necessitating stringent regulatory safeguards to mitigate its exposure during gestation. Despite its tumultuous pharmacovigilance history, culminating in significant international moratoria due to catastrophic fetal outcomes, thalidomide has been rehabilitated into clinical practice under rigorous control, receiving FDA approval in 1998 for oncological and autoimmune indications and gaining inclusion in the WHO List of Essential Medicines, reflecting its critical therapeutic value in modern medicine.", "refusal": null, "annotations": []}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 582, "completion_tokens": 260, "total_tokens": 842, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 0, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": "fp_92f14e8683"}}, "error": null}
{"id": "batch_req_67fc1ff8eff8819082b3937353b748db", "custom_id": "Rofecoxib-complexify", "response": {"status_code": 200, "request_id": "4d1e8cb16c821941ca87d37462bfa161", "body": {"id": "chatcmpl-BLyK6hIqvm9Yb2R9zJQZypFFlmx2y", "object": "chat.completion", "created": 1744576470, "model": "gpt-4o-2024-08-06", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Rofecoxib, a COX-2-selective NSAID, was originally indicated for various arthritic conditions, acute pain, migraines, and dysmenorrhea, until its market withdrawal in 2004 due to augmented cardiovascular (CV) risks, particularly myocardial infarction and cerebrovascular accidents, linked to prolonged high-dosage utilization. The drug's comparative pharmacodynamic profile achieved specificity towards cyclooxygenase-2 isoform inhibition, theoretically minimizing gastrointestinal mucosal compromise yet correlating with increased thromboembolic events, a risk shared by nonselective NSAIDs per longitudinal clinical evaluation. Despite its market retraction, an orphan drug designation was granted to Tremeau Pharmaceuticals in 2017 for rofecoxib (TRM-201) targeting hemophilic arthropathy (HA), a condition necessitating analgesic intervention devoid of NSAID-induced platelet inhibition or opioid dependency, thereby providing a unique therapeutic niche given the absence of other approved agents for HA in the U.S., a population at risk due to recurrent hemarthroses and its degenerative sequelae.", "refusal": null, "annotations": []}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 695, "completion_tokens": 222, "total_tokens": 917, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 0, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": "fp_92f14e8683"}}, "error": null}
{"id": "batch_req_67fc1ff901fc8190aaf11c9cf9da75ce", "custom_id": "Amiloride-complexify", "response": {"status_code": 200, "request_id": "592452ec6c5584719f423e2811b6235e", "body": {"id": "chatcmpl-BLyK2d4TNrdlZD65r1udUq9fT7ce6", "object": "chat.completion", "created": 1744576466, "model": "gpt-4o-2024-08-06", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Amiloride, marketed as Midamor, is a potassium-sparing diuretic frequently employed adjunctively with thiazide or loop diuretics for managing hypertension and edematous states associated with heart failure or hepatic cirrhosis, administered orally. Its pharmacodynamic profile is characterized by inhibition of epithelial sodium channels (ENaC) within the late distal convoluted tubule, connecting tubule, and collecting duct, culminating in attenuated sodium reabsorption and concurrent preservation of potassium levels, manifested as reduced urinary potassium excretion. The pharmacokinetic parameters indicate a two-hour onset of action with a duration spanning approximately 24 hours. Adverse effects predominantly encompass hyperkalemia, pertinent to individuals with renal impairment, advanced age, or diabetes mellitus, along with gastrointestinal disturbances, dermatological reactions, and cephalalgia.", "refusal": null, "annotations": []}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 364, "completion_tokens": 168, "total_tokens": 532, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 0, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": "fp_92f14e8683"}}, "error": null}
{"id": "batch_req_67fc1ff915888190a97db2a9fd335944", "custom_id": "Modafinil-complexify", "response": {"status_code": 200, "request_id": "145ee4fd26bce3015050805aaef5f052", "body": {"id": "chatcmpl-BLyK4fY9lGpbgqD93mtqO3yPtyX6z", "object": "chat.completion", "created": 1744576468, "model": "gpt-4o-2024-08-06", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Modafinil, chemically a CNS stimulant and eugeroic agent, is principally administered for narcolepsy but extends its indication to obstructive sleep apnea and shift work sleep disorder to augment wakefulness through oral administration. Although it is pharmacologically effective at ameliorating excessive somnolence, the drug's safety profile denotes common adverse effects such as anxiety, insomnia, dizziness, and cephalalgia, with potential for severe hypersensitivity reactions and psychiatric sequelae. Given its restricted clearance for populations under 17 by the FDA, usage mandates caution, notably in teratogenic contexts, as prenatal exposure may provoke fetal harm. Its application as a nootropic for cognitive augmentation in non-sleep deprived cohorts presents ambiguous outcomes, with literature delineating mixed efficacy on attention and executive function metrics, thereby juxtaposing potential off-label abuse against dubious therapeutic gains.", "refusal": null, "annotations": []}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 400, "completion_tokens": 171, "total_tokens": 571, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 0, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": "fp_92f14e8683"}}, "error": null}
{"id": "batch_req_67fc1ff92ac081909a774e0e2528b7ca", "custom_id": "Zolpidem-complexify", "response": {"status_code": 200, "request_id": "069fbb11177743633c9f6eb02db89a59", "body": {"id": "chatcmpl-BLyK2Ya1f92jm5jc4aAGS3DL2j0A2", "object": "chat.completion", "created": 1744576466, "model": "gpt-4o-2024-08-06", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Zolpidem is a nonbenzodiazepine hypnotic agent, distinguished pharmacologically as an imidazopyridine and classified as a Z-drug, primarily indicated for the short-term amelioration of insomnia. Its therapeutic efficacy in decreasing sleep latency, quantified as approximately a 15-minute reduction in sleep onset, is attributed to its function as a positive allosteric modulator of the GABAA receptor, thereby potentiating inhibitory GABAergic transmission in the central nervous system by binding at sites akin to benzodiazepines. Pharmacokinetically, zolpidem exhibits a biphasic elimination with a half-life averaging 2 to 3 hours, extended in hepatic impairment, necessitating careful dose adjustments. Administered orally, it is formulated as immediate-release, extended-release, and sublingual tablets, with dosing typically post-behavioral interventions such as CBT-I and sleep hygiene practices. Adverse effect profiles include, but are not limited to, somnolence, cephalalgia, nausea, and potential neuropsychiatric disturbances like amnesia and visual/auditory hallucinations, warranting consideration of flumazenil antagonism in overdose scenarios albeit primarily managed with supportive measures. Zolpidem's controlled substance designation under Schedule IV in the US reflects its abuse potential, underscored by its high prescription frequency with over 9 million prescriptions annually, placing it as a prominent therapeutic option for sleep disorders.", "refusal": null, "annotations": []}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 514, "completion_tokens": 293, "total_tokens": 807, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 0, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": "fp_92f14e8683"}}, "error": null}
{"id": "batch_req_67fc1ff93e8081908558d326983875dc", "custom_id": "Perindopril-complexify", "response": {"status_code": 200, "request_id": "d2d2ed78d1ba94ee8ead575455b2c4ac", "body": {"id": "chatcmpl-BLyK2UbmlYHZRrVYVZz1Y27xeJ7dg", "object": "chat.completion", "created": 1744576466, "model": "gpt-4o-2024-08-06", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Perindopril, a potent long-acting angiotensin-converting enzyme (ACE) inhibitor, effectively mitigates hypertensive states, heart failure, and stable coronary artery disease by obstructing angiotensin II synthesis, a critical vasopressor, thereby engendering vasodilation and augmented natriuresis, cumulatively attenuating systemic vascular resistance and volumetric load. The prodrug, perindopril, undergoes hepatic biotransformation to its active moiety, perindoprilat, exerting pharmacological efficacy through increased plasma renin activity and suppressed aldosterone biosynthesis, resulting in enhanced sodium excretion. Administered as perindopril arginine/amlodipine or perindopril erbumine, these formulations remain bioequivalent yet necessitate dosage adjustments for optimal equipotent dosing. Due to teratogenic potential, its usage is contraindicated during gestation, and hypersensitivity reactions alongside adverse events such as persistent cough, cephalalgia, vertigo, gastrointestinal disturbances represent common tolerability issues.", "refusal": null, "annotations": []}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 406, "completion_tokens": 215, "total_tokens": 621, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 0, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": "fp_92f14e8683"}}, "error": null}
{"id": "batch_req_67fc1ff952c08190b8b50892b9b88a2b", "custom_id": "Ketamine-complexify", "response": {"status_code": 200, "request_id": "22d895c96270d90852122d47e7f7023a", "body": {"id": "chatcmpl-BLyK58E7Gh3sDC6ZkWAeedza9UktD", "object": "chat.completion", "created": 1744576469, "model": "gpt-4o-2024-08-06", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Ketamine, a phencyclidine derivative, serves as a non-competitive NMDA receptor antagonist, primarily utilized in clinical anesthesiology for induction and maintenance due to its unique ability to induce a state of dissociative anesthesia characterized by analgesia, sedation, and amnesia, while preserving autonomic reflexes, respiratory function, and cardiovascular stimulatory effects, such as increased cardiac output and moderate bronchodilation. Its pharmacokinetics allow lower, sub-anesthetic dosages to mitigate treatment-resistant depression and chronic pain, although the attenuation of therapeutic effects with time necessitates repeated administrations or adjunctive strategies. Despite its clinical utilities, ketamine's dissociative and hallucinogenic properties foster its illicit recreational use, often termed \"Special K,\" with prurience towards both nascent and profound psychotropic experiences, compounded by long-term hepatic and lower urinary tract toxicity risks in habitual users. The drug\u2019s presence spans both human and veterinary medicine, underscored by its inclusion on the WHO's List of Essential Medicines, reflecting its essential pharmacological versatility and accessibility as a generic formulation.", "refusal": null, "annotations": []}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 464, "completion_tokens": 220, "total_tokens": 684, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 0, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": "fp_92f14e8683"}}, "error": null}
{"id": "batch_req_67fc1ff963988190a899914c2ebeecb9", "custom_id": "Chloroquine-complexify", "response": {"status_code": 200, "request_id": "ada9582d2fa98167b0f220cf0be2e76f", "body": {"id": "chatcmpl-BLyK2BwEphgTmP4uvNKmnOhSSkN4K", "object": "chat.completion", "created": 1744576466, "model": "gpt-4o-2024-08-06", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Chloroquine, a 4-aminoquinoline class antiparasitic agent, primarily exerts its antimalarial effects by disrupting Plasmodium spp. asexual intraerythrocytic stages through the accumulation of toxic haem within the parasite's acidic food vacuoles, thus hindering haemozoin biocrystallization and ultimately leading to plasmodicidal activity. Resistance phenomena necessitate adjunctive or alternative therapeutics, particularly among certain Plasmodium falciparum isolates. Beyond malaria, chloroquine demonstrates efficacy in extra-intestinal amoebiasis and provides therapeutic benefit in autoimmune conditions such as rheumatoid arthritis and systemic lupus erythematosus, though the mechanistic pathways in these diseases remain elusive. Orally administered, chloroquine's adverse profile includes neuromuscular, dermatological, and gastrointestinal disturbances, with severe toxicities encompassing retinopathy, cardiomyopathy, and hematologic dyscrasias. Despite exploratory investigations during the COVID-19 pandemic, the NIH advises against its use due to inefficacious outcomes in controlled trials. Chloroquine's inclusion in the World Health Organization's compendium of essential medicines underscores its indispensable role in therapeutics, and its established genetic availability ensures widespread access.", "refusal": null, "annotations": []}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 429, "completion_tokens": 249, "total_tokens": 678, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 0, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": "fp_92f14e8683"}}, "error": null}
{"id": "batch_req_67fc1ff9752881908e28519a69a31d60", "custom_id": "Pyridostigmine-complexify", "response": {"status_code": 200, "request_id": "261552a91ea7573e1d5775e5604d6b66", "body": {"id": "chatcmpl-BLyK24LDwA122VXyRnzP9jq3ZMJ8G", "object": "chat.completion", "created": 1744576466, "model": "gpt-4o-2024-08-06", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Pyridostigmine, a quaternary ammonium acetylcholinesterase inhibitor, augments synaptic acetylcholine concentrations by inhibiting its enzymatic hydrolysis, thus enhancing cholinergic transmission at neuromuscular junctions. Primarily indicated for the symptomatic management of myasthenia gravis and neurogenic bladder dysfunction, pyridostigmine also plays a pivotal role in reversing neuromuscular blockade induced by non-depolarizing agents, particularly when administered concomitantly with atropine to mitigate muscarinic side effects. Off-label, it addresses dysautonomia in certain variants of Postural Orthostatic Tachycardia Syndrome. Administered orally or via parenteral routes, it exhibits an onset of action at approximately 45 minutes with a pharmacodynamic tenure spanning up to four hours. Adverse effects manifest predominantly as gastrointestinal disturbances such as nausea and diarrhea, though hypotension, skeletal muscle weakness, and hypersensitivity reactions present significant risks. Its safety profile during gestation remains indeterminate. As an agent of the cholinergic pharmacotherapeutic class, pyridostigmine is enshrined in the World Health Organization's compendium of essential medications and is available in generic formulations.", "refusal": null, "annotations": []}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 378, "completion_tokens": 250, "total_tokens": 628, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 0, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": "fp_92f14e8683"}}, "error": null}
{"id": "batch_req_67fc1ff9874c8190a81c969919578144", "custom_id": "Sumatriptan-complexify", "response": {"status_code": 200, "request_id": "6861c4f3e4d76412231bf0d1e154b85e", "body": {"id": "chatcmpl-BLyK3OcxBzIO2sABHZbSarfQD0Pnt", "object": "chat.completion", "created": 1744576467, "model": "gpt-4o-2024-08-06", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Sumatriptan, a triptan-class pharmacologic agent, serves as a selective agonist for serotonin 5-HT1B and 5-HT1D receptors, exerting its antimigraine efficacy via vasoconstrictive and neuronal inhibition pathways. Administrable via oral, nasal, or subcutaneous routes, sumatriptan yields therapeutic outcomes in migraine and cluster headache relief typically within a three-hour post-administration window. While the precise mechanistic underpinnings remain somewhat ambiguous, its receptor specificity precipitates adverse effects like chest pressure, fatigue, emesis, paraesthesia, and dizziness, with potential for inducing severe pathologies such as serotonin syndrome, myocardial infarction, cerebrovascular accidents, and convulsive events. Chronic or excessive application can instigate medication overuse headaches, and its safety profile remains inconclusive during gestation and lactation. Despite these considerations, its clinical utility is underscored by its inclusion on the World Health Organization's List of Essential Medicines, availability in generic forms, and its prescription prevalence. Sumatriptan exhibits ready incorporation into combination therapies, such as with naproxen, to enhance therapeutic efficacy.", "refusal": null, "annotations": []}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 379, "completion_tokens": 232, "total_tokens": 611, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 0, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": "fp_92f14e8683"}}, "error": null}
{"id": "batch_req_67fc1ff999788190b2f524fa31eaa510", "custom_id": "Carvedilol-complexify", "response": {"status_code": 200, "request_id": "6bbc19e986c9b8259fece06a64d7a578", "body": {"id": "chatcmpl-BLyK5gtgmJL748PZdv4IPjlzgxNHp", "object": "chat.completion", "created": 1744576469, "model": "gpt-4o-2024-08-06", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Carvedilol, a nonselective beta-adrenergic blocker with alpha-1 adrenergic receptor antagonism, is clinically utilized for managing hypertension and chronic heart failure with reduced ejection fraction (HFrEF), often despite beta-blockers not being preferred first-line antihypertensives due to inferior cardiovascular outcomes and safety profiles relative to alternative hypertensives. While its pharmacodynamic mechanisms contributing to therapeutic efficacy in HFrEF remain incompletely elucidated, vasodilation resultant from alpha-1 blockade may play a role. Adverse reactions encompass orthostatic hypotension, asthenia, arthralgia, nausea, and dyspnea, with bronchospasm as a potential severe manifestation. The drug's pharmacokinetics necessitate cautious use during gestation and lactation and contraindicate administration in hepatic impairment cases. Despite exhibiting a broad safety spectrum, carvedilol's utilization extends to over 17 million annual prescriptions in the U.S., affirming its presence on the WHO's List of Essential Medicines and availability in generic formulations.", "refusal": null, "annotations": []}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 406, "completion_tokens": 214, "total_tokens": 620, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 0, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": "fp_92f14e8683"}}, "error": null}
{"id": "batch_req_67fc1ff9ac2881909e3e987c00093eb8", "custom_id": "Zafirlukast-complexify", "response": {"status_code": 200, "request_id": "b97e76ff485ee14ef34002f8e561d55a", "body": {"id": "chatcmpl-BLyK8M45YFDuMrrukknyjrqQ69Gkz", "object": "chat.completion", "created": 1744576472, "model": "gpt-4o-2024-08-06", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Zafirlukast, an orally bioavailable leukotriene receptor antagonist, targets the cysteinyl leukotriene receptor subtypes CysLT1, thereby attenuating leukotriene-mediated bronchoconstriction, microvascular permeability, and airway inflammation pivotal in the asthma pathophysiology. While generally well tolerated, adverse reactions include cephalalgia and gastrointestinal disturbances; however, hepatotoxicity such as fulminant hepatic failure and eosinophilic granulomatosis with polyangiitis have been sporadically reported, though the latter lacks a definitive causal linkage. Zafirlukast undergoes extensive hepatic biotransformation via the cytochrome P450 2C9 isoenzyme, with consequential inhibition of CYP3A4, delineating a potential for pharmacokinetic drug-drug interactions. Polymorphisms in LTC4 synthase and cytochrome P450 2C9 may modulate individual response variability to this pharmacotherapy.", "refusal": null, "annotations": []}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 426, "completion_tokens": 195, "total_tokens": 621, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 0, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": "fp_a6dfaf2bcf"}}, "error": null}
{"id": "batch_req_67fc1ff9c0a8819080d02e37914ff07a", "custom_id": "Amlodipine-complexify", "response": {"status_code": 200, "request_id": "ed4677b9c0435a0b5245cfa60e37d9ec", "body": {"id": "chatcmpl-BLyKALAq88GFi6ihBc88eemlKNcVw", "object": "chat.completion", "created": 1744576474, "model": "gpt-4o-2024-08-06", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Amlodipine, a dihydropyridine-type long-acting calcium channel antagonist, exerts its pharmacological action primarily through vasodilation by impeding calcium ion influx through L-type calcium channels in vascular smooth muscle, which ameliorates hypertension, coronary artery disease, and variant angina. Administered orally, its pharmacokinetic profile necessitates caution in hepatic impairment and geriatric populations, requiring dose modulation. Although the teratogenic risk during gestation or lactation remains indeterminate, its side effect profile encompasses peripheral edema, lethargy, gastrointestinal distress, and potential hypotension or myocardial infarction. This compound's significant therapeutic utility has merited its inclusion on the WHO Essential Medicines List and extensive global prescription prevalence while remaining generically accessible.", "refusal": null, "annotations": []}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 399, "completion_tokens": 157, "total_tokens": 556, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 0, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": "fp_a6dfaf2bcf"}}, "error": null}
{"id": "batch_req_67fc1ff9d3dc8190a7f711b8ac9beee0", "custom_id": "Ondansetron-complexify", "response": {"status_code": 200, "request_id": "e22351b3d0055e7fcf3ca23516157463", "body": {"id": "chatcmpl-BLyKCPshPBqbxOEFZkLLXg2lPnhj0", "object": "chat.completion", "created": 1744576476, "model": "gpt-4o-2024-08-06", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Ondansetron, a potent antiemetic utilized to mitigate nausea and emesis associated with chemotherapy, radiation, migraine, and surgical procedures, exerts its pharmacological action as a selective serotonin 5-HT3 receptor antagonist. Absence of affinity for dopaminergic and muscarinic acetylcholine receptors precludes extrapyramidal side effects such as akathisia. Administered via oral, intravenous, or intramuscular routes, ondansetron's pharmacokinetic profile is characterized by hepatic metabolism and renal excretion. Adverse effects frequently reported encompass gastrointestinal dysmotility manifesting as diarrhea or constipation, central nervous system manifestations including headache and somnolence, and dermal pruritus, with more severe toxicities including QT interval prolongation on electrocardiographic assessment and anaphylaxis. Although the teratogenic risk is minimal, comprehensive teratological data in gravid populations remain insufficient. Recognized on the WHO's List of Essential Medicines, ondansetron is extensively prescribed, highlighting its clinical utility and incorporation into treatment protocols, with significant utilization confirmed by its high prescription frequency in the United States.", "refusal": null, "annotations": []}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 368, "completion_tokens": 226, "total_tokens": 594, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 0, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": "fp_92f14e8683"}}, "error": null}
{"id": "batch_req_67fc1ff9e49c8190a7a057f0571e7d32", "custom_id": "Temozolomide-complexify", "response": {"status_code": 200, "request_id": "9fe140d81ac300f0b4274cdd37f26942", "body": {"id": "chatcmpl-BLyKEYTujBEOpBcKudO7XPtHbn6Dj", "object": "chat.completion", "created": 1744576478, "model": "gpt-4o-2024-08-06", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Temozolomide is a cytotoxic alkylating agent employed primarily in neuro-oncology for the management of high-grade gliomas, including glioblastoma multiforme and anaplastic astrocytoma, administered orally or intravenously. The therapeutic action involves DNA methylation at the O6 and N7 positions of guanine, leading to DNA strand breaks and apoptosis, particularly effective in the presence of MGMT promoter methylation, enhancing chemosensitivity. Adverse hematologic effects largely manifest as myelosuppression, including neutropenia, lymphopenia, and thrombocytopenia, alongside gastrointestinal disturbances such as emesis and anorexia, dermatological reactions typified by alopecia and rash, and neurological symptoms like convulsions and fatigue. Additionally, temozolomide's synergistic efficacy with PARP inhibitors, notably olaparib, extends its utility in salvage therapy for recalcitrant malignancies like relapsed small cell lung cancer, augmenting its strategic application in oncology pharmacotherapy.", "refusal": null, "annotations": []}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 364, "completion_tokens": 207, "total_tokens": 571, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 0, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": "fp_92f14e8683"}}, "error": null}
{"id": "batch_req_67fc1ff9f76481909e0fb1f8bf699215", "custom_id": "hydralazine-complexify", "response": {"status_code": 200, "request_id": "2b1ddcca56ffb6085bab26d3805a9364", "body": {"id": "chatcmpl-BLyK4otxDyGVGXBdiWOQvXLLGmezC", "object": "chat.completion", "created": 1744576468, "model": "gpt-4o-2024-08-06", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Hydralazine, a direct-acting vasodilator, primarily functions by eliciting arteriolar smooth muscle relaxation leading to decreased peripheral resistance and afterload, effectively lowering systemic blood pressure, particularly useful in hypertensive emergencies and heart failure. Its mechanism involves interference with intracellular calcium dynamics and modulation of nitric oxide signaling, highly favored in conjunction with isosorbide dinitrate for African American patients presenting with heart failure. Its pharmacokinetics reveal an onset of action approximately 15 minutes post-administration, with bioavailability subjected to first-pass metabolism, and a duration of effect extending up to six hours. Contraindications include coronary artery disease and mitral valvulopathy secondary to rheumatic heart disease, and caution is warranted in renal impairment necessitating dosage adjustments. Adverse effects, such as reflex tachycardia and cephalalgia, stem from compensatory sympathetic activation, thus contraindicating use in tachycardiac or CAD patients. Its inclusion on the WHO's List of Essential Medicines underscores its clinical significance, albeit it is low-cost and widely utilized, reflecting its extensive prescription volume.", "refusal": null, "annotations": []}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 380, "completion_tokens": 222, "total_tokens": 602, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 0, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": "fp_92f14e8683"}}, "error": null}
{"id": "batch_req_67fc1ffa093881909c948d5d287f960f", "custom_id": "Ibuprofen-complexify", "response": {"status_code": 200, "request_id": "cb9b77326e5d6a5efb83ba47a96ee45c", "body": {"id": "chatcmpl-BLyK6DuPUdgoYQCSg7wNjeu4AopzB", "object": "chat.completion", "created": 1744576470, "model": "gpt-4o-2024-08-06", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Ibuprofen, a widely utilized nonsteroidal anti-inflammatory drug (NSAID), exerts its therapeutic effects primarily through the attenuation of cyclooxygenase (COX) enzymatic activity, thereby reducing the biosynthesis of pro-inflammatory prostaglandins. Indicated for alleviating nociceptive and inflammatory perturbations such as dysmenorrhea, migrainous episodes, and inflammatory arthropathies, ibuprofen demonstrates notable pharmacokinetics with onset of action within one hour post administration via oral or parenteral routes. Despite its efficacy, ibuprofen's pharmacodynamic profile correlates with several adverse outcomes, notably gastrointestinal mucosal irritation leading to potential bleeding, renal impairment with prolonged administration, and rare hepatotoxicity. It possesses a variable cardiovascular risk profile, posing increased myocardial infarction risk at higher dosages. Notably, ibuprofen is contraindicated in advanced gestational periods due to its deleterious fetal effects and can exacerbate asthmatic conditions. Although it constitutes a less potent anti-inflammatory than other NSAIDs, its inclusion in the WHO's List of Essential Medicines underscores its clinical utility across various domains. Despite its prevalence, ongoing vigilance is advised due to its side effect spectrum.", "refusal": null, "annotations": []}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 498, "completion_tokens": 242, "total_tokens": 740, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 0, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": "fp_a6dfaf2bcf"}}, "error": null}
{"id": "batch_req_67fc1ffa1b848190a49bb97e793e42e9", "custom_id": "phenytoin-complexify", "response": {"status_code": 200, "request_id": "eba157a7b664d84ee856dd94ae1850c7", "body": {"id": "chatcmpl-BLyK9qEh7QOrcOLMI9Kzgq7ffxaJa", "object": "chat.completion", "created": 1744576473, "model": "gpt-4o-2024-08-06", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Phenytoin (PHT), marketed as Dilantin, is a hydantoin derivative functioning as a voltage-gated sodium channel inhibitor, efficacious in mitigating hyperexcitable neuronal circuits characteristic of tonic-clonic and focal seizures, yet ineffective against absence seizures. Its prodrug, fosphenytoin, is formulated for intravenous administration to manage benzodiazepine-refractory status epilepticus. Pharmacokinetics reveal rapid onset within 30 minutes post-intravenous administration, with a therapeutic window extending approximately 24 hours; plasma concentration monitoring is imperative for dosage calibration. Adverse effects range from benign, such as gastrointestinal disturbances, to serious, including cerebellar degeneration, toxic epidermal necrolysis, and hematological suppression. Teratogenicity is documented, contraindicating its use in pregnancy, though lactation appears unaffected. Ethanol co-administration may perturb its antiepileptic efficacy. Despite the presence of a myriad of generic versions, phenytoin remains listed by WHO as essential due to its distinct pharmacodynamic profile and is widely prescribed, underscoring its significance in the therapeutic armamentarium for seizure disorders.", "refusal": null, "annotations": []}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 462, "completion_tokens": 234, "total_tokens": 696, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 0, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": "fp_92f14e8683"}}, "error": null}
{"id": "batch_req_67fc1ffa2e1481909a5d8f069187509e", "custom_id": "Imatinib-complexify", "response": {"status_code": 200, "request_id": "75840f5a50d04e170158534c5f458ba7", "body": {"id": "chatcmpl-BLyKChlWiNYUH7wPJpC2WplUXU2PE", "object": "chat.completion", "created": 1744576476, "model": "gpt-4o-2024-08-06", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Imatinib, branded as Gleevec and Glivec, is an orally administered ATP-competitive small molecule inhibitor with specificity against a range of tyrosine kinases, including CSF1R, BCR-ABL, c-KIT, FLT3, and PDGFR-\u03b2, making it a pivotal treatment in Philadelphia chromosome-positive chronic myelogenous leukemia (CML) and acute lymphoblastic leukemia (ALL), alongside applications in gastrointestinal stromal tumors (GIST), hypereosinophilic syndrome (HES), chronic eosinophilic leukemia (CEL), systemic mastocytosis, and myelodysplastic syndrome. Its mechanism involves the inhibition of the fusion protein Bcr-Abl tyrosine kinase, thereby impeding proliferative signaling cascades and inducing apoptosis in neoplastic cells. Notable adverse reactions encompass gastrointestinal disturbances, musculoskeletal discomfort, cephalalgia, dermatological manifestations, with more severe toxicities such as edema, myelosuppression, hemorrhagic events, hepatotoxicity, and cardiac dysfunction; moreover, teratogenic potential mandates cautious use during gestation. Imatinib's recognition by the World Health Organization as essential highlights its critical role in oncologic pharmacopeia, with a generic formulation introduced into the UK market in 2017.", "refusal": null, "annotations": []}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 423, "completion_tokens": 264, "total_tokens": 687, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 0, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": "fp_a6dfaf2bcf"}}, "error": null}
{"id": "batch_req_67fc1ffa3fdc8190af93fae187d59d78", "custom_id": "hydroxychloroquine-complexify", "response": {"status_code": 200, "request_id": "4a551d169b36bf94ef17594d861b44ea", "body": {"id": "chatcmpl-BLyKE3HC8dKx0Kp6k3vikEHveVBNo", "object": "chat.completion", "created": 1744576478, "model": "gpt-4o-2024-08-06", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Hydroxychloroquine, chemically classified within the 4-aminoquinoline antimalarial pharmacophore, is primarily indicated for malaria prophylaxis and therapeutic intervention in chloroquine-sensitive endemic regions, while possessing secondary applications in autoimmune pathologies such as rheumatoid arthritis and lupus erythematosus, and hereditary porphyrias like porphyria cutanea tarda. Orally administered as hydroxychloroquine sulfate, its pharmacodynamics entail immunomodulation potentially via interference with lysosomal activity and autophagy processes. Adverse effects range from gastrointestinal disturbances and neuromuscular impairments to severe toxicities, including irreversible retinopathy, potentially through phototoxic damage, cardiovascular arrhythmias, possibly via QT interval prolongation, and hypersensitivity reactions. Despite teratogenic risks, its teratogenicity remains unsubstantiated, enabling cautious use in rheumatic conditions during gestation. Although initial studies erroneously posited an antiviral efficacy against SARS-CoV-2, subsequent rigorously controlled clinical trials delineated a lack of efficacy coupled with a propensity for adverse events, jeopardizing drug availability for FDA-approved conditions. Consequently, hydroxychloroquine's role in COVID-19 treatment is widely contraindicated, reaffirming its therapeutic utilization within its defined medicinal scope.", "refusal": null, "annotations": []}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 436, "completion_tokens": 254, "total_tokens": 690, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 0, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": "fp_92f14e8683"}}, "error": null}
{"id": "batch_req_67fc1ffa52448190b454656ccadfe0fd", "custom_id": "Bumetanide-complexify", "response": {"status_code": 200, "request_id": "92ff09013a93f757313e56980e75e239", "body": {"id": "chatcmpl-BLyK4qkmPPLGa17hZpfKFZh12kxFJ", "object": "chat.completion", "created": 1744576468, "model": "gpt-4o-2024-08-06", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Bumetanide, a potent loop diuretic prominently utilized for amelioration of edema due to congestive heart failure, hepatic cirrhosis, or renal insufficiency, operates by robustly inhibiting the sodium-potassium-chloride cotransporter in the thick ascending limb of Henle's loop, consequently attenuating sodium reabsorption, enhancing natriuresis and diuresis. Although not the antihypertensive of first choice, its rapid onset post-oral or parenteral administration\u2014manifesting within one hour with a diuretic effect persisting approximately six hours\u2014renders it efficacious in scenarios refractory to alternative agents. The pharmacodynamic profile necessitates vigilant monitoring for electrolyte imbalances, notably hypokalemia, and adverse nephrological manifestations, in addition to more rare ototoxic and hematologic complications. Routine laboratory evaluations, including serum electrolytes and renal function tests, are advocated during therapy. Bumetanide's teratogenic risks remain inconclusive, advising prudence during gestation and lactation. The extensive clinical utilization underscores its inclusion in the World Health Organization\u2019s compendium of essential medicines, despite its preferential status as a secondary option in hypertension management.", "refusal": null, "annotations": []}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 378, "completion_tokens": 241, "total_tokens": 619, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 0, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": "fp_a6dfaf2bcf"}}, "error": null}
{"id": "batch_req_67fc1ffa65e88190b7dfeeecea82e1b4", "custom_id": "Naproxen-complexify", "response": {"status_code": 200, "request_id": "a5d8a545235cfbcffdc18853dc69218a", "body": {"id": "chatcmpl-BLyK4l5dIp3cYJxscyf6wgLGs2IKw", "object": "chat.completion", "created": 1744576468, "model": "gpt-4o-2024-08-06", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Naproxen, a nonsteroidal anti-inflammatory drug (NSAID), exerts its pharmacological effects by non-selectively inhibiting cyclooxygenase (COX) enzymes, thereby attenuating the synthesis of pro-inflammatory prostaglandins, which are pivotal in the pathophysiology of pain, menstrual dysmenorrhea, and inflammatory diseases such as rheumatoid arthritis and gout. Administered orally in both immediate and delayed-release formulations, naproxen reaches therapeutic plasma concentrations within one hour, with a duration of action extending up to twelve hours, facilitating its utility in both acute and chronic settings. The sodium salt variant enhances oral solubility and absorption kinetics. While commonly associated with adverse effects including gastrointestinal discomfort, dizziness, and hypersensitivity reactions, more severe risks include cardiovascular thrombotic events and gastrointestinal bleeding, albeit with potentially a lower myocardial infarction risk relative to other NSAIDs. Its use is contraindicated in the presence of renal impairment and during the third trimester of pregnancy. Metabolic clearance occurs hepatically via biotransformation to inactive metabolites, with excretion primarily renal. Naproxen's widespread prescription, evident from over 7 million prescriptions in 2022 in the U.S., underscores its established therapeutic role, despite the potential for adverse event profiles.", "refusal": null, "annotations": []}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 439, "completion_tokens": 259, "total_tokens": 698, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 0, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": "fp_92f14e8683"}}, "error": null}
{"id": "batch_req_67fc1ffaa15081908819f4a14f139f21", "custom_id": "Metronidazole-complexify", "response": {"status_code": 200, "request_id": "872126d44a86ed00531af37fda6c9a01", "body": {"id": "chatcmpl-BLyK7p390F1YYW5iR66VVZ0ipEqWN", "object": "chat.completion", "created": 1744576471, "model": "gpt-4o-2024-08-06", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Metronidazole, a nitroimidazole antimicrobial agent, exerts its therapeutic efficacy through the reductive activation of its nitro group under anaerobic conditions, leading to the generation of radical intermediates that disrupt nucleic acid synthesis and result in microbial cell death. This antimicrobial exhibits a broad spectrum of antiprotozoal and antibacterial activity, making it efficacious in treating a variety of conditions, including pelvic inflammatory disease, bacterial vaginosis, and anaerobic infections such as Clostridioides difficile colitis, particularly when first-line options like vancomycin are unavailable. Pharmacodynamically, metronidazole can be administered via oral, topical, or intravenous routes, allowing flexibility in clinical application. However, its use is occasionally accompanied by adverse reactions such as gastrointestinal disturbances, neurotoxicity including seizures, and hypersensitivity responses, necessitating cautious application, particularly in pregnant populations where teratogenic potential is debated, though generally compatible with lactation. Despite these considerations, metronidazole remains a cornerstone in antimicrobial treatment paradigms, reflected by its inclusion in the WHO's List of Essential Medicines and high prescription rates globally.", "refusal": null, "annotations": []}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 411, "completion_tokens": 231, "total_tokens": 642, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 0, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": "fp_a6dfaf2bcf"}}, "error": null}
{"id": "batch_req_67fc1ffab51c8190a4e737df8afe3dba", "custom_id": "Lidocaine-complexify", "response": {"status_code": 200, "request_id": "20cf24988c935e5d040202dff14c2c79", "body": {"id": "chatcmpl-BLyK9naU4zs2Wz3uRLlNKDx8asGKA", "object": "chat.completion", "created": 1744576473, "model": "gpt-4o-2024-08-06", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Lidocaine, or lignocaine, is a quintessential amino amide local anesthetic utilized extensively for its neuromodulatory and cardiac electrophysiological properties. As a class Ib antiarrhythmic agent, lidocaine exerts its mechanistic effect via blockade of voltage-gated sodium channels, thereby attenuating myocardial depolarization and stabilizing aberrant conduction pathways responsible for ventricular tachycardia and fibrillation. Its onset of action, contingent upon peripheral nerve administration, is typically rapid, achieving effective anesthesia within minutes, with a duration ranging from 30 minutes to three hours, and efficacy can be potentiated when co-administered with adrenaline due to vasoconstriction and augmented tissue retention. Topical formulations enhance transdermal absorption for sensory blockade across dermal and mucosal surfaces. In systemic circulation, particularly when administered intravenously, lidocaine may induce neurotoxic side effects including CNS agitation, visual disturbances, paresthesia, and emesis, in addition to cardiovascular effects such as hypotension and dysrhythmogenesis. Caution is advised with intra-articular administration due to chondrotoxicity concerns, and dose adjustments are necessary in hepatic insufficiency, yet it remains a favorable option in patients with hypersensitivity to ester-type anesthetics like tetracaine. Due to its obstetric safety profile, lidocaine is deemed viable during gestation and its inclusion in the WHO's List of Essential Medicines underlines its critical therapeutic value and accessibility as a generic formulation.", "refusal": null, "annotations": []}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 474, "completion_tokens": 299, "total_tokens": 773, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 0, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": "fp_a6dfaf2bcf"}}, "error": null}
{"id": "batch_req_67fc1ffaccd88190a477eeb7aec509a4", "custom_id": "Tramadol-complexify", "response": {"status_code": 200, "request_id": "1d60399d493fdd26d66428ba0f7c1f55", "body": {"id": "chatcmpl-BLyK52MV5LEaVd6qHPyDaJIDO91So", "object": "chat.completion", "created": 1744576469, "model": "gpt-4o-2024-08-06", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Tramadol is an atypical analgesic integrating opioid and monoaminergic mechanisms, with dual action as a \u03bc-opioid receptor agonist and serotonin-norepinephrine reuptake inhibitor (SNRI), indicated for moderate to severe pain management. The immediate-release oral formulation facilitates rapid analgesic onset approximately within sixty minutes, and the drug is also administrable via parenteral routes. Metabolically, tramadol undergoes hepatic biotransformation to O-desmethyltramadol (desmetramadol), demonstrating enhanced \u03bc-receptor binding affinity. Adverse effects parallel opioid pharmacodynamics, encompassing gastrointestinal dysmotility resulting in constipation, pruritus, and emesis; with noteworthy risks of seizures, serotonergic toxicity, central nervous system depression, and dependency potential. Renal or hepatic impairments necessitate dose adjustments, while contraindications include pregnancy, lactation (although minimal risk after a solitary dose), and suicidality predispositions. Tramadol is frequently dispensed in combination with acetaminophen and is extensively available under multiple brand denominations and as a generic formulation.", "refusal": null, "annotations": []}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 456, "completion_tokens": 220, "total_tokens": 676, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 0, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": "fp_a6dfaf2bcf"}}, "error": null}
{"id": "batch_req_67fc1ffadfec8190874cc16a050cf7e6", "custom_id": "Amphetamine-complexify", "response": {"status_code": 200, "request_id": "378f7c6ced7c5409c6f21054c1499108", "body": {"id": "chatcmpl-BLyK8DNz30lZFD2LduxLGQMnHNZrZ", "object": "chat.completion", "created": 1744576472, "model": "gpt-4o-2024-08-06", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Amphetamine (alpha-methylphenethylamine), a prototypical phenethylamine and substituted amphetamine, acts as a potent central nervous system (CNS) stimulant, primarily augmenting norepinephrine and dopamine neurotransmission. It exists as racemic mixtures of its enantiomers, dextroamphetamine and levoamphetamine, used therapeutically in attention deficit hyperactivity disorder (ADHD), narcolepsy, and as lisdexamfetamine for binge eating disorder. Its sympathomimetic effects at prescribed doses manifest as euphoria, heightened alertness, cognitive enhancement, and anorectic effects, whereas supratherapeutic dosing can precipitate neurotoxicological outcomes such as dopamine dysregulation, leading to hallucinations, delusions, and sympathomimetic toxicity, including rhabdomyolysis. The pharmacodynamics involve promoting synaptic release and inhibiting reuptake of monoamines. Structurally related to endogenous trace amines like phenethylamine and N-methylphenethylamine, amphetamine has a notable abuse potential with illicit use often exceeding therapeutic dosages, thereby enhancing risk of addiction and psychosis. Historically, its derivatives have included drugs like bupropion, cathinone, MDMA, and methamphetamine, sharing mechanistic overlap in monoaminergic modulation. Therapeutically, amphetamine is available as racemic mixtures or as stereospecific formulations such as Adderall and dextroamphetamine, with its clinical applications intricately regulated given its high potential for misuse.", "refusal": null, "annotations": []}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 757, "completion_tokens": 306, "total_tokens": 1063, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 0, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": "fp_92f14e8683"}}, "error": null}
{"id": "batch_req_67fc1ffaf31081908130d99b418c0e5f", "custom_id": "Pyrimethamine-complexify", "response": {"status_code": 200, "request_id": "6048c774ebd9466353c1cecd0fdc0666", "body": {"id": "chatcmpl-BLyKBTiOyHFGbDwUIS8Im323gLvvd", "object": "chat.completion", "created": 1744576475, "model": "gpt-4o-2024-08-06", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Pyrimethamine, a folic acid antagonist deployed primarily in conjunction with leucovorin to mitigate its hematological toxicity, serves as a therapeutic agent against Toxoplasma gondii and Cystoisospora belli infections. Leveraged as a second-line prophylactic strategy when paired with dapsone, it targets Pneumocystis jiroveci pneumonia in HIV/AIDS cohorts, though its historical anti-malarial application has waned due to resistance. The pharmacological mechanism centers on the inhibition of dihydrofolate reductase, disrupting protozoal DNA synthesis and cell replication. Clinically, the oral administration of pyrimethamine necessitates vigilance due to adverse effects, notably gastrointestinal distress, hypersensitivity reactions, and potential for bone marrow suppression, contraindicating its application in folate-deficient anemia. Oncology concerns persist about its carcinogenic potential, and its teratogenicity risk mandates caution during gestation. Despite these concerns, pyrimethamine retains its status as a World Health Organization Essential Medicine and was ratified as a generic option in the U.S. pharmacopoeia as of early 2020.", "refusal": null, "annotations": []}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 406, "completion_tokens": 230, "total_tokens": 636, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 0, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": "fp_92f14e8683"}}, "error": null}
{"id": "batch_req_67fc1ffb06e0819094deb060d9cbb381", "custom_id": "Lamivudine-complexify", "response": {"status_code": 200, "request_id": "eb1754474b29899e3a6cff19ac19a3d4", "body": {"id": "chatcmpl-BLyK53xKS58j6DufPDP0EgXKtFs6X", "object": "chat.completion", "created": 1744576469, "model": "gpt-4o-2024-08-06", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Lamivudine, or 3TC, is a nucleoside reverse transcriptase inhibitor with efficacy against HIV-1, HIV-2, and chronic hepatitis B virus. It functions by competitive inhibition of HIV reverse transcriptase and hepatitis B virus polymerase, disrupting viral DNA synthesis. Clinically, lamivudine is integral to combination antiretroviral therapy, often co-administered with agents such as zidovudine, dolutegravir, and abacavir, and forms part of post-exposure prophylactic regimens. It is available for oral administration as liquid or tablet formulations, maintaining therapeutic flexibility through its dosing independence from food intake. While generally well-tolerated, adverse effects can include gastrointestinal disturbances, cephalalgia, asthenia, and respiratory symptoms; however, clinicians must vigilantly monitor for hepatotoxicity, lactic acidosis, and hepatitis B exacerbations. Suitable for patients over three months and deemed safe in pregnancy, lamivudine is recognized as an essential medicine, underscoring its pivotal role in antiretroviral pharmacotherapy despite potential genotypic resistance mutations.", "refusal": null, "annotations": []}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 401, "completion_tokens": 228, "total_tokens": 629, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 0, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": "fp_92f14e8683"}}, "error": null}
{"id": "batch_req_67fc1ffb1a7c8190b102d0908744e319", "custom_id": "mercaptopurine-complexify", "response": {"status_code": 200, "request_id": "243c00ac0f86295ea95e00d207f0b115", "body": {"id": "chatcmpl-BLyK7GcK9Sjr8lt3V0rAmcwPfhNb3", "object": "chat.completion", "created": 1744576471, "model": "gpt-4o-2024-08-06", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Mercaptopurine, a thiopurine analogue and antimetabolite, exerts its pharmacological action by interfering with purine nucleotide synthesis, thereby inhibiting the proliferation of rapidly dividing cells such as malignant and immune cells. Its primary clinical applications include the management of hematological malignancies like acute lymphocytic leukemia (ALL) and acute promyelocytic leukemia (APL), as well as the modulation of aberrant immune responses in conditions such as Crohn's disease and ulcerative colitis. Mercaptopurine is administered orally and often in conjunction with methotrexate for synergistic effects in ALL. Its pharmacokinetics is significantly influenced by polymorphisms in thiopurine S-methyltransferase (TPMT), with TPMT deficiency resulting in elevated risk of myelosuppression and other toxicities. Hepatotoxicity, gastrointestinal disturbances, and anorexia are amongst its prevalent adverse effects, while more severe sequelae include heightened oncogenic potential and pancreatitis. Its teratogenic potential contraindicates use in pregnancy. As a cornerstone of chemotherapeutic regimens, mercaptopurine is recognized on WHO's List of Essential Medicines.", "refusal": null, "annotations": []}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 342, "completion_tokens": 238, "total_tokens": 580, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 0, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": "fp_a6dfaf2bcf"}}, "error": null}
{"id": "batch_req_67fc1ffb2cdc81909e36ae6f17c5ca13", "custom_id": "chlortalidone-complexify", "response": {"status_code": 200, "request_id": "11b5586731cbdbb3809fd71e7f0d57f9", "body": {"id": "chatcmpl-BLyK6IMegLKNNtcniMPoiqcSuIjmR", "object": "chat.completion", "created": 1744576470, "model": "gpt-4o-2024-08-06", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Chlortalidone, a thiazide-like sulfonamide diuretic, is predominantly prescribed for antihypertensive therapy and states of edema associated with heart failure, hepatic cirrhosis, and nephrotic syndrome, as well as for managing nephrogenic diabetes insipidus and renal tubular acidosis. Its pharmacodynamic efficacy stems from modulating renal sodium and water excretion, thereby affecting volume and pressure homeostasis; the precise mechanistic pathways, however, remain partially elucidated. Its pharmacokinetic profile reveals oral bioavailability with an onset of diuresis within approximately three hours, sustaining therapeutic effects for up to 72 hours. Comparative studies suggest chlortalidone's superior cardiovascular outcome efficacy over hydrochlorothiazide in long-term stroke and myocardial infarction prophylaxis, despite a contentious spectrum of adverse effect profiles, including hypokalemia, hyponatremia, hyperglycemia, orthostatic hypotension, and reduced erectile function, alongside rarer occurrences of gout, hypomagnesemia, hypercalcemia, and hypersensitivity reactions. Pregnancy use, although possible, is approached with caution due to alternative preferred therapeutics. As part of the WHO's essential medicines list, chlortalidone remains a critical agent in hypertension management, widely available as a cost-effective generic, reflecting its substantial utilization in clinical practice.", "refusal": null, "annotations": []}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 469, "completion_tokens": 273, "total_tokens": 742, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 0, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": "fp_a6dfaf2bcf"}}, "error": null}
{"id": "batch_req_67fc1ffb3fa08190928b28e8c57d8be3", "custom_id": "oxybutynin-complexify", "response": {"status_code": 200, "request_id": "bf92cb72e84ae2ee48912f1d1c609bdb", "body": {"id": "chatcmpl-BLyK7q3Yzo8BHVaYyj2IkvAdiEpV5", "object": "chat.completion", "created": 1744576471, "model": "gpt-4o-2024-08-06", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Oxybutynin, marketed as Ditropan, is a quintessential anticholinergic agent employed predominantly for the amelioration of overactive bladder symptoms, capitalizing on its potent antimuscarinic properties that effectively circumvent acetylcholine-mediated smooth muscle contractions. Its pharmacotherapeutic action, analogous to tolterodine, darifenacin, and solifenacin, renders it a superior first-line therapeutic option due to its robust safety and efficacy profile over prolonged usage, despite plausible off-label utilizations in hyperhidrosis management. Contrarily, its application for pediatric nocturnal enuresis has seen diminished prevalence, given its questionable efficacy. Administrable orally or transdermally, oxybutynin's pharmacokinetic profile necessitates vigilance regarding adverse effects such as xerostomia, gastrointestinal hypomotility, and thermoregulatory dysfunction, encompassing severe sequelae like urinary retention and thermophilic impairments manifesting as heat stroke. Its teratogenic and lactogenic safety paradigms remain speculative, underscoring the need for judicious administration during pregnancy and lactation. As a generically available pharmacologic entity, it maintains substantial prescription frequency, embodying a pivotal role in managing cholinergic-mediated urological disorders.", "refusal": null, "annotations": []}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 423, "completion_tokens": 252, "total_tokens": 675, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 0, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": "fp_92f14e8683"}}, "error": null}
{"id": "batch_req_67fc1ffb5298819097b026548eb5b2f6", "custom_id": "Cetirizine-complexify", "response": {"status_code": 200, "request_id": "2984789513da58b6aa7becb5c2ac3620", "body": {"id": "chatcmpl-BLyK7nCmOLdRuQ8TDtRsLKpmTKr7P", "object": "chat.completion", "created": 1744576471, "model": "gpt-4o-2024-08-06", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Cetirizine, a second-generation selective H1 antihistaminergic agent, is primarily administered orally for the amelioration of allergic rhinitis, dermatitis, and urticaria, exerting its pharmacodynamic effects predominantly extracellularly, thereby minimizing central nervous system penetration and consequent sedative effects typical of first-generation antihistamines such as diphenhydramine. Its clinical onset transpires within thirty minutes, maintaining therapeutic efficacy for approximately 24 hours with an adverse effect profile that includes somnolence, xerostomia, cephalalgia, and abdominal discomfort, albeit with a diminished proclivity for sedation compared to its first-generation counterparts due to its peripheral selectivity. Amongst its second-generation analogs, cetirizine exhibits a comparatively higher incidence of somnolence vis-\u00e0-vis fexofenadine and loratadine. It is contraindicated in lactation but permissible during gestation and extends its utility to pediatric cohorts with caution advised regarding potential somnolence. Being generically available and included in the World Health Organization's List of Essential Medicines, cetirizine\u2019s broad prescriptive prevalence, as evidenced by over 13 million US prescriptions in 2022, underscores its efficacy and widespread utilitarian value in allergy management.", "refusal": null, "annotations": []}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 436, "completion_tokens": 250, "total_tokens": 686, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 0, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": "fp_92f14e8683"}}, "error": null}
{"id": "batch_req_67fc1ffb77d48190a51647082aca7d34", "custom_id": "Aciclovir-complexify", "response": {"status_code": 200, "request_id": "2b969d6061acb679d48b5a9fdd1c8488", "body": {"id": "chatcmpl-BLyKA3OIyBuklXTsaLtLVzb6uAPo2", "object": "chat.completion", "created": 1744576474, "model": "gpt-4o-2024-08-06", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Aciclovir, an antiviral guanosine analogue, exhibits its therapeutic efficacy predominantly by inhibiting viral DNA polymerase through its metabolization to aciclovir triphosphate, resulting in the cessation of herpesvirus DNA elongation across Herpes Simplex Virus, varicella-zoster, and CMV prophylaxis post-transplantation. Administerable orally, topically, or intravenously, its pharmacokinetic profile necessitates careful consideration in patients with compromised renal or hepatic function due to potential nephrotoxicity and thrombocytopenia. While demonstrating an acceptable safety margin during gestation and lactation, adverse events such as gastrointestinal discomfort and diarrhea are common. Its inclusion in the WHO's Essential Medicines list underscores its global pivotal role in antiviral therapy, with its generic accessibility enhancing universal healthcare implementation.", "refusal": null, "annotations": []}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 388, "completion_tokens": 165, "total_tokens": 553, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 0, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": "fp_92f14e8683"}}, "error": null}
{"id": "batch_req_67fc1ffb8a588190925b8eec574b2f31", "custom_id": "vincristine-complexify", "response": {"status_code": 200, "request_id": "49447165de5450a057a6ceb829d85083", "body": {"id": "chatcmpl-BLyK9Qgr01B2N6BYIHx0AzY2XSdVs", "object": "chat.completion", "created": 1744576473, "model": "gpt-4o-2024-08-06", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Vincristine, a vinca alkaloid derived from Catharanthus roseus, acts as a mitotic inhibitor by binding to tubulin, thus disrupting microtubule assembly and arresting metaphase progression in neoplastic cells. Clinically administered intravenously, it exhibits therapeutic efficacy against malignancies such as acute lymphoblastic leukemia, acute myeloid leukemia, Hodgkin's lymphoma, neuroblastoma, and small cell lung carcinoma. Its pharmacological profile is marked by both neuropathic and systemic side effects, including peripheral neuropathy, alopecia, gastrointestinal stasis, and neuromuscular impairments, alongside potential for severe toxicities like myelosuppression and pulmonary compromise. Teratogenic risks contraindicate its use in gravid patients. Owing to its profound neurotoxicity, inadvertent intrathecal administration can precipitate fatal outcomes, underscoring the critical importance of adhering to strict administration protocols. Recognized for its oncologic utility, vincristine remains a cornerstone agent within chemotherapeutic regimens and is listed on the WHO's Essential Medicines index.", "refusal": null, "annotations": []}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 355, "completion_tokens": 220, "total_tokens": 575, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 0, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": "fp_92f14e8683"}}, "error": null}
{"id": "batch_req_67fc1ffb9e488190bb000b4a15fba451", "custom_id": "Fluphenazine-complexify", "response": {"status_code": 200, "request_id": "54c022cd6782c1ab9e3c265d41379ab2", "body": {"id": "chatcmpl-BLyKCik7sAQ5hhoJtCm7Gd7PFeu7p", "object": "chat.completion", "created": 1744576476, "model": "gpt-4o-2024-08-06", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Fluphenazine is a high-affinity typical antipsychotic of the phenothiazine cohort primarily prescribed for chronic psychotic disorders such as schizophrenia, offering efficacy comparable to chlorpromazine. Administered via oral, intramuscular, subcutaneous routes\u2014or as a long-acting depot, fluphenazine decanoate\u2014this compound exhibits prolonged dopaminergic antagonism with an extended half-life conducive to monthly dosing regimens. Notably contraindicated in severe depressive states, its pharmacological action is ascribed to dopamine receptor blockade, though precision in its mechanism remains indeterminate. The pharmacodynamic profile of fluphenazine entails extrapyramidal symptoms, somnolence, depressive mood alterations, and metabolic side effects, with grave adverse events encompassing neuroleptic malignant syndrome, agranulocytosis, and irreversible tardive dyskinesia. Moreover, in the geriatric cohort with dementia-related psychoses, mortality risk is potentiated. Prolactin secretion perturbations may elicit galactorrhea, gynecomastia, erectile dysfunction, and amenorrhea, with teratogenic safety in gestation unresolved. Chronic administration associates with hepatocellular enzyme elevation in a substantial patient subset. Despite its broad utilization reflected in its inclusion on the World Health Organization's Essential Medicines list, its production cessation in some regions underscores its dynamic availability landscape.", "refusal": null, "annotations": []}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 479, "completion_tokens": 278, "total_tokens": 757, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 0, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": "fp_92f14e8683"}}, "error": null}
{"id": "batch_req_67fc1ffbb1848190b2958fb6aaf78c1c", "custom_id": "Alprazolam-complexify", "response": {"status_code": 200, "request_id": "6f30d71424eb407f08f2975ffea4c517", "body": {"id": "chatcmpl-BLyKCJbLAzMqoinL2WphnMjHNr0eo", "object": "chat.completion", "created": 1744576476, "model": "gpt-4o-2024-08-06", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Alprazolam is a high-affinity triazolobenzodiazepine functioning as a potent anxiolytic agent through modulation of the GABA_A receptor chloride channel activity, facilitating enhanced inhibitory neurotransmission. Its pharmacodynamic profile encompasses rapid onset and moderate duration of action, predominantly prescribed for anxiety spectrum disorders, including panic disorder and GAD, and adjunctively for chemotherapy-related emesis control. The pharmacokinetic trajectory involves oral administration, exhibiting bioavailability conducive to therapeutic efficacy within a week for GAD. The acute adverse neurological sequelae are characterized by CNS depression manifesting as somnolence, psychomotor impairment, cognitive attenuation, and dose-dependent anterograde amnesia. Tolerance development mitigates some sedative effects over time. Abrupt cessation precipitates benzodiazepine withdrawal symptomatology. As a Schedule IV controlled substance, alprazolam's potential for abuse and dependency necessitates judicious prescription monitoring. Its clinical ubiquity is substantiated by its standing as the 41st most prescribed drug in the US, with significant generic dissemination.", "refusal": null, "annotations": []}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 463, "completion_tokens": 220, "total_tokens": 683, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 0, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": "fp_92f14e8683"}}, "error": null}
{"id": "batch_req_67fc1ffbc3808190bb0321b97fdf29a8", "custom_id": "Emtricitabine-complexify", "response": {"status_code": 200, "request_id": "245199cccd4b6a4223a8d926c4d1e83a", "body": {"id": "chatcmpl-BLyKEB5aupiK2EUg0yZ2ne39txzL2", "object": "chat.completion", "created": 1744576478, "model": "gpt-4o-2024-08-06", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Emtricitabine (FTC; 2',3'-dideoxy-5-fluoro-3'-thiacytidine) operates as a potent nucleoside reverse-transcriptase inhibitor (NRTI) indicated for both prophylaxis and active management of HIV infection across diverse age cohorts. This molecule is integral to the composition of the Quad pill, specifically Stribild and Genvoya, and is prominently featured in fixed-dose co-formulations with tenofovir disoproxil as Truvada and with tenofovir alafenamide as Descovy, underscoring its critical role in multi-drug regimens. Emtricitabine's strategic inclusion in these combinations has earned it placement on the WHO's List of Essential Medicines, reflecting its indispensable utility in comprehensive antiretroviral therapy. Notably, the FDA-approved fixed-dose triple combination incorporating emtricitabine, tenofovir, and efavirenz, commercially available as Atripla, exemplifies its integration into optimized antiretroviral protocols aimed at maximizing therapeutic efficacy and medication adherence.", "refusal": null, "annotations": []}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 418, "completion_tokens": 220, "total_tokens": 638, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 0, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": "fp_a6dfaf2bcf"}}, "error": null}
{"id": "batch_req_67fc1ffbd5308190bf6e777218f7bc09", "custom_id": "acetazolamide-complexify", "response": {"status_code": 200, "request_id": "bfaa26d6ca493412ecc72793488acc40", "body": {"id": "chatcmpl-BLyKER6Buu5w0ZCN6HPQVJyQGZMgn", "object": "chat.completion", "created": 1744576478, "model": "gpt-4o-2024-08-06", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Acetazolamide, marketed under the trade name Diamox, serves as a versatile pharmaceutical agent within the realm of carbonic anhydrase inhibitors, effectively modulating intraocular pressure via the diminution of aqueous humor production and osmolality. Its clinical utility spans across conditions such as glaucoma\u2014both open-angle and acute angle closure\u2014epilepsy, acute mountain sickness, periodic paralysis, idiopathic intracranial hypertension, and heart failure, with an ancillary role in urinary alkalinization. Therapeutic administration is achievable through oral and intravenous modalities. Mechanistically, acetazolamide exerts its effects by disrupting the equilibria of carbon dioxide hydration and subsequent bicarbonate ion production, thereby reducing intracellular hydrogen ion availability. The pharmacodynamic profile encompasses neuro-sensory side effects like paresthesia and tinnitus, alongside anorexia, emesis, and somnolence. Contraindications are notable in individuals with renal or hepatic impairment, and those with hypersensitivity to sulfonamide derivatives. As a diuretic and enzymatic inhibitor, it holds a position on the WHO's List of Essential Medicines, emphasizing its critical global accessibility as a generic formulation.", "refusal": null, "annotations": []}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 389, "completion_tokens": 230, "total_tokens": 619, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 0, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": "fp_a6dfaf2bcf"}}, "error": null}
{"id": "batch_req_67fc1ffbe78c81909ab7e735b5c6b9ae", "custom_id": "Paracetamol-complexify", "response": {"status_code": 200, "request_id": "c3c1c99cc5f6221121ae2358d84c2ff4", "body": {"id": "chatcmpl-BLyKHWEPG7BsGohFgVf9Vo6ZN2hex", "object": "chat.completion", "created": 1744576481, "model": "gpt-4o-2024-08-06", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Paracetamol, or acetaminophen, functions as a para-aminophenol derivative providing analgesic and antipyretic effects predominantly by inhibiting COX enzymes within the central nervous system; however, its peripheral anti-inflammatory impact is minimal compared to nonsteroidal anti-inflammatory drugs (NSAIDs) like ibuprofen. It is therapeutically advantageous for alleviating mild to moderate pain in conditions such as acute mild migraine and episodic tension headaches, though the analgesic efficacy is modest in osteoarthritic and low back pain contexts, with negligible evidence supporting its utility in cancer and neuropathic pain management. Paracetamol at standard dosing mitigates fever to a limited extent; however, it is suboptimal compared to ibuprofen, particularly in febrile states of viral etiology, rendering its role in antipyresis debatable. Despite its generally safe profile when administered short-term and adherence to a maximum recommended dosage of three to four grams daily, paracetamol harbors hepatotoxic potential when overdosed, being a preeminent cause of drug-induced acute hepatic failure in Western populations. Its metabolic pathway in the liver, involving cytochrome P450 enzymes and subsequent depletion of glutathione reserves, underscores the mechanism of hepatotoxicity. Chronic use may elicit gastrointestinal bleeding and hepatic dysfunction, whereas its utilization might be beneficial for patients contraindicated for NSAID therapy. Clinically, combination therapies, such as with ibuprofen, exhibit increased analgesic efficacy, while the triple combination of aspirin, paracetamol, and caffeine remains a preferred first-line intervention for mild pain syndromes. Paracetamol\u2019s clinical application persists widely, inscribed on the World Health Organization's List of Essential Medicines, and forecasts substantial prescription numbers globally.", "refusal": null, "annotations": []}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 640, "completion_tokens": 352, "total_tokens": 992, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 0, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": "fp_92f14e8683"}}, "error": null}
{"id": "batch_req_67fc1ffbfda481909adc8ce0bf6f6c63", "custom_id": "Metoprolol-complexify", "response": {"status_code": 200, "request_id": "bf7064bb415679eb609701114a5a956f", "body": {"id": "chatcmpl-BLyKGwMakyGXzDI4GDE9NABlrwoEb", "object": "chat.completion", "created": 1744576480, "model": "gpt-4o-2024-08-06", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Metoprolol, a cardioselective \u03b21-adrenergic receptor antagonist, is clinically utilized in the management of angina pectoris, hypertension, tachyarrhythmias, post-myocardial infarction secondary prophylaxis, and migraine prophylaxis. Its therapeutic efficacy is mediated via negative chronotropic and inotropic effects which result in decreased myocardial oxygen demand and improved exercise tolerance. The pharmacokinetics of metoprolol is influenced by hepatic cytochrome P450 2D6 isoenzyme variability leading to significant interpatient variability in drug metabolism, necessitating individualized dosing. Adverse effects prominently include insomnia, asthenia, presyncope, and gastrointestinal disturbances, with higher doses presenting risk for pronounced toxicity. Though teratogenic risk during pregnancy has not been conclusively excluded, its excretion into breast milk is considered clinically insignificant. Metoprolol is widely dispensed, reflecting its inclusion in the WHO's Essential Medicines, and its prescription frequency underscores its pivotal role in cardiovascular therapeutics.", "refusal": null, "annotations": []}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 372, "completion_tokens": 206, "total_tokens": 578, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 0, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": "fp_22890b9c0a"}}, "error": null}
{"id": "batch_req_67fc1ffc148c819093db85470b8396b2", "custom_id": "Ketorolac-complexify", "response": {"status_code": 200, "request_id": "30dd1f467da4ee3e29ac1c166cfdf333", "body": {"id": "chatcmpl-BLyKLPpFY81o4QPhCC6XA0Zu8CASW", "object": "chat.completion", "created": 1744576485, "model": "gpt-4o-2024-08-06", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Ketorolac, marketed under names such as Toradol, Acular, and Sprix, is a potent nonsteroidal anti-inflammatory drug (NSAID) indicated for the management of moderate to severe nociceptive pain with a treatment limitation not exceeding six to seven days, varying by country guidelines. Administration routes include oral, nasal, intravenous, intramuscular, and ophthalmic, with onset of analgesia within one hour and duration of efficacy up to eight hours. Its mechanism of action involves the inhibition of cyclooxygenase enzymes 1 and 2 (COX-1 and COX-2), resulting in the attenuation of prostaglandin synthesis, and it possesses ancillary antipyretic properties. Common adverse reactions encompass sedation, vertigo, gastrointestinal discomfort, and emesis, while severe complications may involve gastrointestinal hemorrhage, nephrotoxicity, myocardial infarction, bronchospasm, heart failure, and hypersensitivity reactions. It is contraindicated in later stages of gestation and lactation due to potential fetal and neonatal risks. Despite its initial appeal as a non-opioid analgesic alternative with lower addictive potential, its correlation with significant adverse outcomes such as gastrointestinal and renal sequelae led to market withdrawal in specific regions like Germany. As a robust prostaglandin synthesis inhibitor, ketorolac compromises renal autoregulation under conditions of hemodynamic stress or elevated catecholamine states, limiting its utilization in those with underlying renal or cardiovascular vulnerabilities.", "refusal": null, "annotations": []}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 546, "completion_tokens": 299, "total_tokens": 845, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 0, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": "fp_22890b9c0a"}}, "error": null}
{"id": "batch_req_67fc1ffc2be48190a19c123d72e4de08", "custom_id": "Brimonidine-complexify", "response": {"status_code": 200, "request_id": "ba3207285026252d4a97e43eaf1f3a5c", "body": {"id": "chatcmpl-BLyK7EyBhVSGDd4GKLnQrHrzYa62H", "object": "chat.completion", "created": 1744576471, "model": "gpt-4o-2024-08-06", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Brimonidine is an \u03b12-adrenergic agonist exhibiting therapeutic efficacy in attenuating open-angle glaucoma and ocular hypertension via modulation of intraocular pressure through dual mechanisms: decreased aqueous humor synthesis and enhanced uveoscleral outflow. Additionally, its vasoconstrictive action on cutaneous vasculature imparts symptomatic relief in erythema associated with rosacea when administered topically. The pharmacological profile is complemented by its inclusion in a fixed-dose compound with timolol maleate, enhancing antihypertensive efficacy. Ocular administration predisposes patients to localized side effects such as conjunctival hyperemia, pruritus, and xerostomia, whereas dermal application manifests as erythema, discomfort, and potential cephalgia. While systemic absorption is minimal, hypersensitivity reactions and hypotensive episodes warrant clinical vigilance. Brimonidine's safety profile in gravid populations is reassuring, and its generically available formulations have solidified its position as a mainstay in ophthalmic and dermatologic therapeutics, underscored by a substantial prescription volume.", "refusal": null, "annotations": []}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 360, "completion_tokens": 215, "total_tokens": 575, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 0, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": "fp_a6dfaf2bcf"}}, "error": null}
{"id": "batch_req_67fc1ffc3e6c819092c4659a1a2b0e9d", "custom_id": "Dobutamine-complexify", "response": {"status_code": 200, "request_id": "fb449f2558568c0956b5e6811aaa3611", "body": {"id": "chatcmpl-BLyK7zsngsC9gaqjdgV4p8lrARV7e", "object": "chat.completion", "created": 1744576471, "model": "gpt-4o-2024-08-06", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Dobutamine, administered intravenously or intraosseously, is an adrenergic agonist specifically targeting \u03b21-adrenergic receptors, eliciting a pronounced inotropic response without significant chronotropic impact, thereby enhancing myocardial contractility and systemic perfusion in the management of cardiogenic shock and severe heart failure. The pharmacokinetics of dobutamine are characterized by rapid onset within two minutes and an elimination half-life of two minutes, necessitating titration to effect and favoring short-term administration, although it may be employed in extended durations in the context of pre-transplant heart failure symptomatology management. Adverse reactions primarily include tachyarrhythmias, injection site reactions, and contraindication in hypertrophic subaortic stenosis. Synthetically derived from isoproterenol, dobutamine has been devoid of significant chronotropic effects, making it distinct among inotropes.", "refusal": null, "annotations": []}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 383, "completion_tokens": 182, "total_tokens": 565, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 0, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": "fp_a6dfaf2bcf"}}, "error": null}
{"id": "batch_req_67fc1ffc50c881908e617149c3f44164", "custom_id": "Citalopram-complexify", "response": {"status_code": 200, "request_id": "80b36ee16a2f3c6f55ceb3d426c47aef", "body": {"id": "chatcmpl-BLyK9RFsogr2ZMPgbGT1OrUWHdC66", "object": "chat.completion", "created": 1744576473, "model": "gpt-4o-2024-08-06", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Citalopram, a chiral bicyclic phthalane derivative and selective serotonin reuptake inhibitor (SSRI), is primarily employed in the pharmacotherapy of major depressive disorder, obsessive-compulsive disorder, panic disorder, and social phobia through modulation of serotonergic neurotransmission. The therapeutic latency ranges from one to four weeks post-administration. It is predominantly administered orally, though parenteral administration via intravenous injection is utilized in specific regions to expedite therapeutic onset. The pharmacokinetic profile of citalopram encompasses hepatic metabolism predominantly via CYP2C19, CYP3A4, and CYP2D6, yielding demethylated metabolites. It is imperative to monitor for adverse reactions, including, but not limited to, gastrointestinal disturbances, insomnia, sexual dysfunction, tremors, somnolence, hyperhidrosis, serotonin toxicity, and cardiotoxicity as manifested by QT interval prolongation. Contraindications entail concurrent MAO inhibitor therapy due to risk of serotonin syndrome and potential teratogenicity warrants cautious use in pregnancy. The potential for exacerbating suicidality in individuals under 25 necessitates vigilant monitoring. Citalopram's clinical prominence is evidenced by its inclusion in the WHO's List of Essential Medicines and its extensive prescribing frequency in the United States, underscoring its integral role in psychiatric treatment regimens.", "refusal": null, "annotations": []}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 420, "completion_tokens": 269, "total_tokens": 689, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 0, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": "fp_a6dfaf2bcf"}}, "error": null}
{"id": "batch_req_67fc1ffc636c8190a0594bd52fd98d56", "custom_id": "Ziprasidone-complexify", "response": {"status_code": 200, "request_id": "8e76fba30624050d1aed1177c783da59", "body": {"id": "chatcmpl-BLyK7LtdjlGxrms2zYTVKDJZlJsmg", "object": "chat.completion", "created": 1744576471, "model": "gpt-4o-2024-08-06", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Ziprasidone, primarily marketed as Geodon, is a second-generation atypical antipsychotic exhibiting therapeutic efficacy in managing both schizophrenia and bipolar disorder, with formulary options for oral and intramuscular (IM) administration. The IM variant, ziprasidone mesylate trihydrate, is particularly leveraged for rapid amelioration of acute agitative states in schizophrenic patients, whereas oral administration utilizes the hydrochloride salt form. The pharmacodynamic profile of ziprasidone suggests a mechanism of action predicated on modulation of serotonergic (5-HT) and dopaminergic (D2) neurotransmitter pathways, although the precise mechanistic underpinnings remain elusive. The adverse effect spectrum spans neuromotor disturbances like tremors and tics, autonomic nervous system effects such as dry mouth and nausea, and characteristic psychotropic-induced sedation. Notably, ziprasidone presents a reduced risk of weight gain compared to its atypical counterparts. Despite its complex pharmacological profile, ziprasidone occupies a significant niche in psychopharmacotherapy, underscored by its prescription prevalence, ranking 282nd in the U.S. pharmaceutical landscape as of 2020 with over a million prescriptions circulated.", "refusal": null, "annotations": []}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 369, "completion_tokens": 250, "total_tokens": 619, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 0, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": "fp_a6dfaf2bcf"}}, "error": null}
{"id": "batch_req_67fc1ffc75dc8190b4d4134e8a4a9076", "custom_id": "Fentanyl-complexify", "response": {"status_code": 200, "request_id": "55d7e576edd650b2dfe4d18674271bea", "body": {"id": "chatcmpl-BLyK8ZinSBuWSeLx9d90u6QhKe1ic", "object": "chat.completion", "created": 1744576472, "model": "gpt-4o-2024-08-06", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Fentanyl, a synthetic piperidine opioid agonist, demonstrates exceptional analgesic efficacy, with \u03bc-opioid receptor affinity rendering it 50-100 times more potent than morphine. Clinically, it is indispensable for managing severe pain in oncologic contexts and post-operative recovery, administered under brand names such as Actiq, Duragesic, and Sublimaze. The pharmacokinetic profile facilitates rapid onset across administration routes, thus posing significant overdose risk even at minimal doses. Adverse pharmacodynamics encompass addiction potential, central nervous system depression leading to respiratory compromise, and a range of neuropsychiatric disturbances, including narcotic delirium and hypotensive coma, exacerbated synergistically by concurrent alcohol or co-ingestants like cocaine and heroin. Although opioid antagonists such as naloxone are efficacious in overdose scenarios, fentanyl\u2019s high receptor occupancy and potency often necessitate multiple reversal attempts. Epidemiologically, fentanyl supersedes other synthetic opioids, catalyzing an overdose epidemic exacerbated by clandestine synthesis and poly-drug formulations, complicating therapeutic interventions and forensic investigations. Proactive measures, including test kits and advanced analytical protocols, are critical in mitigating rampant illicit distribution, underpinned by fentanyl\u2019s streamlined synthesis and distribution adaptability.", "refusal": null, "annotations": []}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 852, "completion_tokens": 255, "total_tokens": 1107, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 0, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": "fp_a6dfaf2bcf"}}, "error": null}
{"id": "batch_req_67fc1ffc89dc8190b26f421ad596a495", "custom_id": "Lamotrigine-complexify", "response": {"status_code": 200, "request_id": "65a48546d2bd7371383395a3542d1a4f", "body": {"id": "chatcmpl-BLyKBpZTJs6RHiP8PBo9vFY0R0a2A", "object": "chat.completion", "created": 1744576475, "model": "gpt-4o-2024-08-06", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Lamotrigine, a phenyltriazine anticonvulsant, is primarily utilized in the pharmacological management of epilepsy, encompassing focal, tonic-clonic, and Lennox-Gastaut syndrome seizures, as well as serving as a mood-stabilizing agent in bipolar disorder. While it does not consistently ameliorate acute depressive states in bipolar disorders outside of severe depression contexts, it efficaciously mitigates the risk of recurrent depressive episodes in euthymic individuals. Additionally, lamotrigine is prescribed off-label for major depressive disorder and depersonalization-derealization disorder. Its pharmacodynamics are hypothesized to involve the inhibition of excitatory neurotransmitter release through modulation of voltage-sensitive sodium channels and voltage-gated calcium channels. Despite its therapeutic efficacy, lamotrigine's adverse effect profile includes both common side effects such as nausea, somnolence, headache, emesis, ataxia, and dermatological reactions, and serious reactions like hemolytic anemia, suicidality, and potentially fatal Stevens\u2013Johnson syndrome.", "refusal": null, "annotations": []}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 468, "completion_tokens": 211, "total_tokens": 679, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 0, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": "fp_92f14e8683"}}, "error": null}
{"id": "batch_req_67fc1ffc9ce48190affac63508059186", "custom_id": "Efavirenz-complexify", "response": {"status_code": 200, "request_id": "d7a4a8e6f155fb4f5b314df7f97f06d8", "body": {"id": "chatcmpl-BLyKEWQMwqIUplQvfKJVV5hS2ozq0", "object": "chat.completion", "created": 1744576478, "model": "gpt-4o-2024-08-06", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Efavirenz, a non-nucleoside reverse transcriptase inhibitor (NNRTI), exerts its antiretroviral efficacy by allosterically inhibiting the HIV-1 reverse transcriptase enzyme, thereby impeding viral DNA synthesis and subsequent viral replication. Typically administered orally, either as a monotherapy or in combination formulations such as efavirenz/emtricitabine/tenofovir, it constitutes a cornerstone in antiretroviral regimens aimed at both therapeutic management and post-exposure prophylaxis in cases of potential HIV transmission exposure, such as needlestick injuries. Despite its clinical efficacy, adverse events such as dermatological eruptions, including Stevens\u2013Johnson syndrome, and neuropsychiatric manifestations, encompassing depression and suicidal ideations, as well as hepatic and neurological disturbances, notably contraindicate its use during pregnancy due to potential teratogenicity. However, due to its clinical importance, evidenced by its inclusion in the World Health Organization's List of Essential Medicines, it remains widely available, including in generic formulations post-patent expiration.", "refusal": null, "annotations": []}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 371, "completion_tokens": 213, "total_tokens": 584, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 0, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": "fp_92f14e8683"}}, "error": null}
{"id": "batch_req_67fc1ffcae688190aba9eca3d34e84e1", "custom_id": "Sildenafil-complexify", "response": {"status_code": 200, "request_id": "4c0f5cd88ecdd2524f2e2210850ce69a", "body": {"id": "chatcmpl-BLyKGdpx91r5ixMTwJyKB9CvZ2aNk", "object": "chat.completion", "created": 1744576480, "model": "gpt-4o-2024-08-06", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Sildenafil functions primarily as a selective inhibitor of phosphodiesterase type 5 (PDE5), the enzyme responsible for catabolizing cyclic guanosine monophosphate (cGMP) in smooth muscle cells. This pharmacological activity results in the potentiation of nitric oxide-mediated vasodilation, thus enhancing blood flow to the corpus cavernosum and mitigating pulmonary arterial hypertension (PAH) through pulmonary vasodilation. The drug's pharmacokinetics include a rapid onset of action, typically within 20 minutes post-oral administration, and a duration of approximately two hours. Its bioavailability can be achieved via oral, intravenous, or sublingual administration. Concomitant use with nitrates or nitric oxide donors can precipitate severe hypotension, contraindicating concomitant administration. Side effects are often attributable to excessive peripheral vasodilation and can include headache, dyspepsia, facial flushing, and rare, albeit severe, adverse events such as vision or auditory impairment and priapism. Precision in its administration is imperative for individuals with cardiovascular pathology due to potential exacerbation of underlying conditions. Although efficacious in ED and PAH, its utility in female sexual dysfunction remains inconclusive.", "refusal": null, "annotations": []}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 487, "completion_tokens": 243, "total_tokens": 730, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 0, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": "fp_92f14e8683"}}, "error": null}
